 
 
 
 
 
 
 
 
 
Clinical Protocol Title :  Short -Term Outcome  of N-Carbamylglutamate in the Treatment  of Acute 
Hyperammonemia .  
 
 
Study Chair:    Nicholas Ah Mew , MD  
Director, Inherited Metabolic Disorders  
Children’s National Research Institute  
Associate Professor of Pediatrics  
The George Washington University  
111 Michigan Ave, NW  
Washington, DC 20010  
nahmew@childrensnational.org  
202-476-5863  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase of Clinical Investigation : Phase II  
 
IND Number:    68,185  
 
Investigational Drug(s) :  N-carbamyl -L-glutamate, N -carbamylglutamate, NCG, Carglumic acid, 
“Carbaglu” (Orphan Europe)  
 
Sponsor :  National Institutes of Health (NIH), Recordati Rare Diseases  This protocol is for research purposes only and should not be copied, redistributed, or used for any 
other purpose. The procedures in this protocol are intended only for use by study investigators in 
carefully controlled settings. The Study Chair of this study should be consulted before using this 
protocol.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 2 of 58 
 Short -Term Outcome of N -Carbamylglutamate in the Treatment of Acute Hyperammonemia  
 
 
Investigator Agreement  
 
Protocol Version 1.0 ……………………………………………………………..... Version Date: May 4, 2012 
Protocol Version 1.1 …………………………………………………...… Version Date: Se ptember 27, 2012 
Protocol Version 1.2 …………………….……………………………………….. Version Date: July 30, 2013 
Protocol Version 2.0 …………………………………………….………… Version Date: September 9, 2014 
Protocol Version 2.1 ……………………………………………………............. Version Date: April 14, 2015 
Protocol Version 3.0 ………………………………………………………. Version Date: September 9, 2016 
Protocol Version 3.1 ……………………………………………………….. Version Date: November 8, 2016 
Protocol Version 4.0 …………………………………………………………..... Version Date: March 6, 2017 
Protocol Version 4.1 ……………………… ……………………………..………. Version Date: May 24, 2017  
Protocol Version 4.2 ………………………………………………………...…. Version Date: August 4, 2017  
Protocol Version 5.0 ………………………………………………………… Version Date: October 17, 2018  
Protocol Version 6.0 ………………………………………………..…………. Version Dat e: March 20, 2019  
Protocol Versi on 7.0 …………………………………………………………...  Version D ate: March 31 , 2020   
Protocol Version 7.1 …………………………………………………………….… Version Date: May 1, 2020  
 
The signature below represents my approval of:  
Protocol Version 7.1 ………………………………………………… ……… …... Version Date: May 1, 2020 
 
 
Study Chair:  Nicholas Ah Mew , MD  
Director, Inherited Metabolic Disorders  
Children's National Research Institute  
Associate Professor of Pediatrics  
The George Washington University  
 
 
 
 
 
Signature:  _____________________________________________            _________________  
            Date  
 
 
Site PI:  _____________________________________________          
 
 
Site:     _____________________________________________          
 
 
Signature:  _________________ ____________________________            _________________  
            Date  
 
 
 
 
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 3 of 58 
 IND Number:    68,185  
 
Sponsor :  National Institutes of Health (NIH), Recordati Rare Diseases  
Table of Contents  
LIST OF PARTICIPATING INSTITUTIONS  ................................ ................................ ...........................  6 
LIST OF CENTRAL ENTITIES  ................................ ................................ ................................ ...............  8 
LIST OF DATA AND SAFETY MONITORING BOARD (DSMB) MEMBERS  ................................ ........  10 
LIST OF ABBREVIATIONS ................................ ................................ ................................ ..................  11 
STUDY SYNOPSIS AND SCHEMA  ................................ ................................ ................................ ..... 12 
1 INTRODUCTION  ................................ ................................ ................................ ..............................  14 
 Background  ................................ ................................ ................................ ..............................  14 1.1
1.1.1  The Urea Cycle  ................................ ................................ ................................ .............  14 
1.1.2  Carbamyl Phosphate Synthetase I Deficiency (CPSD)  ................................ .................  14 
1.1.3  Ornithine Transcarbamylase Deficiency (OTCD)  ................................ ..........................  14 
1.1.4  Propionic Acidemia (PA)  ................................ ................................ ...............................  15 
1.1.5  Methylmalonic Acidemia (MMA)  ................................ ................................ ....................  15 
1.1.6  Mechanism of Hyperammonemia in PA and MMA  ................................ ........................  15 
1.1.7  Current Therapies for Hyperammonemia  ................................ ................................ ...... 15 
 Study Rationale  ................................ ................................ ................................ ........................  16 1.2
 Study Treatment: N -carbamyl -L-glutamate (NCG)  ................................ ................................ .... 17 1.3
1.3.1  Preclinical Profile  ................................ ................................ ................................ ..........  17 
1.3.2  Clinical Profile  ................................ ................................ ................................ ...............  18 
1.3.3  Carbaglu Formulation and Dosage  ................................ ................................ ...............  19 
1.3.4  Safety and Side Effects of Carbaglu  ................................ ................................ .............  20 
2 OBJECTIVES  ................................ ................................ ................................ ................................ ... 21 
2.3.1.1  ................................ ................................ ................................ ................................ ..............  21 
 Assess Efficacy of NCG Treatment  ................................ ................................ ..........................  21 2.1
 Safety  ................................ ................................ ................................ ................................ ....... 21 2.2
3 STUDY DESIGN  ................................ ................................ ................................ ...............................  22 
3.3.1.1  ................................ ................................ ................................ ................................ ..............  22 
 Overview of Stud y Design  ................................ ................................ ................................ ........  22 3.1
4 STUDY POPULATION  ................................ ................................ ................................ ......................  24 
4.3.1.1  ................................ ................................ ................................ ................................ ..............  24 
 Inclusion Criteria  ................................ ................................ ................................ ......................  24 4.1
 Exclusion Criteria  ................................ ................................ ................................ .....................  24 4.2
5 STUD Y PROCEDURES  ................................ ................................ ................................ ...................  25 
5.3.1.1  ................................ ................................ ................................ ................................ ..............  25 
 Screening of Potential Subjects  ................................ ................................ ................................  25 5.1
5.1.1  Confirmation of Diagnosis of PA, MMA, CPSD or OTCD  ................................ ..............  25 
 Informed Consent Procedures  ................................ ................................ ................................ .. 25 5.2
 Retention Procedures  ................................ ................................ ................................ ...............  26 5.3
 Duration of Study and Visit Schedule  ................................ ................................ .......................  27 5.4
5.4.1  Hyperammonemia Episodes  ................................ ................................ .........................  27 
 Study Assessments  ................................ ................................ ................................ ..................  30 5.5
5.5.1  Laboratory Tests  ................................ ................................ ................................ ...........  30 
5.5.2  Electrocardiogram Test (EKG)  ................................ ................................ ......................  31 
5.5.3  Transfusion Information  ................................ ................................ ................................  31 
5.5.4  Clinical Assessments  ................................ ................................ ................................ .... 31 
5.5.5  Efficacy Assessments  ................................ ................................ ................................ ... 32 
5.5.6  Safety Assessments  ................................ ................................ ................................ ..... 32 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 4 of 58 
  Treatment Compliance  ................................ ................................ ................................ .............  33 5.6
 Study Termination/Stopping Rules  ................................ ................................ ...........................  33 5.7
 Subject Discontinuation  ................................ ................................ ................................ ............  33 5.8
 Blinding  ................................ ................................ ................................ ................................ .... 33 5.9
5.9.1  Type of Blinding  ................................ ................................ ................................ ............  33 
5.9.2  Maintenance of Blinding  ................................ ................................ ...............................  33 
5.9.3  Breaking the Blinding  ................................ ................................ ................................ .... 34 
6 STUDY TREATMENTS  ................................ ................................ ................................ ....................  35 
6.1 Study Intervention  ................................ ................................ ................................ ....................  35 
6.2 Control (Placebo) Intervention  ................................ ................................ ................................ .. 35 
6.3 Dispensing of Study Medications ................................ ................................ ..............................  35 
6.4 Provisions for Access to Investigational Treatment after Study  ................................ ................  35 
6.5 Drug Packaging/Handling/Storage/Accountability  ................................ ................................ ..... 35 
6.6 Concomitant Therapy  ................................ ................................ ................................ ...............  36 
6.6.1 Therapies Prohibited Before/During the Trial  ................................ ................................  36 
6.6.2  Therapies Allowed During the Trial  ................................ ................................ ...............  36 
7 SAFETY MONITORING  ................................ ................................ ................................ ....................  37 
7.1 Adve rse Events (AEs)  ................................ ................................ ................................ ..............  37 
7.1.1  Definitions  ................................ ................................ ................................ .....................  37 
7.1.2  Collection and Reporting of Adverse Events  ................................ ................................ . 39 
7.2 Data and Safety Monitoring Board (DSMB)  ................................ ................................ ..............  41 
7.3 Medical Monitor  ................................ ................................ ................................ ........................  41 
8 STATISTICAL ANALYSIS  ................................ ................................ ................................ .................  42 
8.1 Study Aims  ................................ ................................ ................................ ...............................  42 
8.1.1  Primary Aim ................................ ................................ ................................ .................  42 
8.1.2  Secondary Aim  ................................ ................................ ................................ ............  42 
8.2 Factors for Stratification  ................................ ................................ ................................ ...........  42 
8.3 Statistical Considerations  ................................ ................................ ................................ .........  42 
8.3.1  Interim Analysis  ................................ ................................ ................................ ............  43 
8.4 Rationale for Sample Size and Statistical Power  ................................ ................................ ...... 44 
9 REGULATORY COMPLIANCE AND SAFETY MONITORING  ................................ ..........................  45 
9.1 Regulatory Compliance  ................................ ................................ ................................ ............  45 
9.2 Statement of Compliance  ................................ ................................ ................................ .........  45 
9.3 Informed Consent  ................................ ................................ ................................ .....................  45 
9.4 Records Retention and Requirements  ................................ ................................ ......................  46 
9.5 Financial Disclosure  ................................ ................................ ................................ .................  46 
9.6 Inclusion of Minorities and Children  ................................ ................................ ..........................  46 
9.7 Confidentiality ................................ ................................ ................................ ...........................  46 
9.7.1  Protection Against Risk  ................................ ................................ ................................ . 46 
9.7.2  Health Insurance Portability and Accountability Act (HIPAA)  ................................ ........  47 
9.8 Regulatory Files  ................................ ................................ ................................ .......................  47 
9.9 Source Data Verification Monitoring  ................................ ................................ .........................  48 
9.10  Modification of the Protocol  ................................ ................................ ................................ ...... 48 
9.11  Protocol Deviations and Violations  ................................ ................................ ...........................  48 
10 DATA MANAGEMENT AND PROCEDURES  ................................ ................................ .................  50 
10.1  Data Collection  ................................ ................................ ................................ .........................  50 
10.2  Data Processing  ................................ ................................ ................................ .......................  50 
10.3  Design and Development of REDCap for Study Data Management  ................................ .........  50 
10.3.1  REDCap Time Event Matrix  ................................ ................................ ..........................  50 
10.3.2  REDCap Protocol Management  ................................ ................................ ....................  51 
10.3.3  REDCap Facilitated Screening Features  ................................ ................................ ...... 51 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 5 of 58 
 10.3.4  REDCap Randomization  ................................ ................................ ...............................  51 
10.4  Recruitment and Retention Monitoring  ................................ ................................ .....................  51 
10.5  Site Data and Study Responsibilities  ................................ ................................ ........................  52 
10.6  CNMC Coordinating Center Responsibilities  ................................ ................................ ............  52 
10.7  Data Security ................................ ................................ ................................ ............................  53 
10.8  Data Acquisition and Entry  ................................ ................................ ................................ ....... 53 
10.9  Data Editing  ................................ ................................ ................................ .............................  54 
10.10  Data Lock and Freeze  ................................ ................................ ................................ ...........  54 
10.11 Data Entry Training  ................................ ................................ ................................ ...............  55 
10.12  Data Quality Assurance  ................................ ................................ ................................ .........  55 
11 PUBLICATIONS AND OTHER RIGHTS  ................................ ................................ .........................  56 
12 REFERENCES  ................................ ................................ ................................ ...............................  57 
 
  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 6 of 58 
 LIST OF PARTICIPATING INSTITUTIONS   
 
Boston Children’s Hospital  
Gerard T. Berry, MD  
Institution:  Boston Children’s Hospital  
Address:  Department of Pediatric Endocrinology  
300 Longwood Ave., # FEGAN10  
Boston, MA 02115  
Phone:  857-218-4636  
Fax: 617-730-4874  
 
University Hospitals of Cleveland Medical Center  
Laura Konczal , MD  
Institution:  University Hospitals of Cleveland Medical Center  
Address:  Center for Human Genetics  
11100 Euclid Avenue  
Lakeside 1500  
Cleveland, OH 44106 -6055  
Phone:  216-844-8567  
Fax: 216-844-7497  
 
The Children’s Hospital of Colorado  
Shawn McCandless, MD  
Institution:  The Children’s Hospital of Colorado  
Address:  13123 E. 16th Ave, B300  
Aurora, CO 80045  
Phone:  303-724-2310   
Fax: 720-777-7322   
 
University of California Los Angeles  
Derek Wong, MD  
Institution:  University of California Los Angeles  
Address:  Division of Genetics  
10833 Le Conte Avenue, CHS 32 -231 
Los Angeles, CA 90095  
Phone:  310-206-6581  
Fax: 310-206-8616  
 
The Children's Hospital of Philadelphia (CHOP)  
Can Ficicioglu, MD, PhD  
Institution:  The Children's Hospital of Philadelphia  
Address:  Division of Human Genetics and Metabolism  
3501 Civic Center Blvd, #9054  
Philadelphia, PA 19104  
Phone:  215-590-3376  
Fax: 267-425-0121  
 
  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 7 of 58 
 Lucile Packard Children's Hospital at Stanford University  
Gregory Enns, MD  
Institution:  Lucile Packard Children’s Hospital at Stanford University  
Address:  Pediatric Genetics  
730 Welch Rd, 2nd Floor  
Palo Alto, CA 94304  
Phone:  650-721-5804  
Fax: 650-498-4555  
 
Children’s National Hospital   
Nicholas Ah Mew, MD  
Institution:  Children’s National Hospital  
Address:  Division of Genetics and Metabolism  
111 Michigan Avenue NW,  
Washington, DC 20010  
Phone:  202-476-5863  
Fax: 202-476-5650  
 
Children’s Hospital Pittsburgh  
Gerard Vockley, MD, PhD  
Institution:  Children’s Hospital Pittsburgh  
Address:  4401 Penn Avenue  
Suite 1200  
Pittsburgh, PA 15224  
Phone:  412-692-7746  
Fax: 412-692-7816  
 
Mount Sinai Hospital  
George Diaz, MD  
Institution:  Mount Sinai Hospital  
Address:  1428 Madison Avenue  
1st Floor, Room AB1 -12 
New York, NY 10029  
Phone:  212-241-6947  
  
 
  
  
  
  
 
 
  
  
 
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 8 of 58 
 LIST OF CENTRAL ENTITIES  
 
Study Principal Investigator  
Nicholas Ah Mew, MD  
Institution:  Children’s National Hospital  
Address:  Division of Genetics and Metabolism  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-5863  
Fax: 202-476-5650  
  
  
Project Manager  
Katie Rice, MPH, CCRP  
Institution:  Children’s National Hospital  
Address:  Children’s National Research Institute  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-6191  
Fax: 202-476-5650  
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 9 of 58 
   
Study Biostatistician  
Robert J. McCarter, ScD  
Institution:  Children’s National Hospital  
Address:  Center for Translational Science  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-3140  
Fax: 202- 476-3425  
Pager:  202-259-4567  
  
Central Pharmacy   
Henry Choi, PharmD  
Institution:  Children’s National Hospital  
Address:  Pharmacy Department  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-2088  
Fax: 202-476-6984  
Pager:  202-259-4132  
  
Medical Monitor  
Barbara Burton, MD  
Institution:  Lurie Children’s Hospital of Chicago  
Address:  225 E Chicago Avenue  
Box MC 59  
Chicago, IL 60611  
Phone:  312-227-6120   
Cell: 312-919-2056  
 
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 10 of 58 
 LIST OF DATA AND SAFETY MONITORING BOARD (DSMB) MEMBERS  
 
DSMB Chair Joan Conry, MD  
Institution:  Children’s National Hospital  
Address:  Center for Translational Science  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-2120  
 
John Van Den Anker, MD, PhD  
Institution:  Children’s National Hospital  
Address:  Center for Translational Science  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-4875  
 
An Massaro,  MD 
Institution:  Children’s National Hospital  
Address:  Center for Neurosciences Research  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-5225  
 
Tomas Silber, MD  
Institution:  Children’s National Hospital  
Address:  Department of Adolescent and Young Adult Medicine  
111 Michigan Avenue NW  
Washington, DC 20010  
Phone:  202-476-3066  
 
Samuel Simmens, PhD, MA  
Institution:  The George Washington University  
Address:  Department of Epidemiology and Biostatistics  
School of Public Health and Health Services  
The George Washington University  
2100 -W Pennsylvania Ave, NW  
8th Floor  
Washington, DC 20037  
Phone:  202-994-7887  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 11 of 58 
 LIST OF ABBREVIATIONS  
AE – Adverse Event  
ALT – Alanine Aminotransferase  
AST – Aspartate Aminotransferase  
BCH – Boston Children’s Hospital  
CBC – Complete Blood Count  
CFR – Code of Federal Regulations  
CHOP – Children’s Hospital of Philadelphia  
CPS1 – Carbamyl Phosphate Synthetase 1  
CPSD – Carbamyl Phosphate Synthetase deficiency  
CRA – Clinical Research Associat es 
CRP – Central Research Pharmacy  
CTCAE – Common Terminology Criteria for Adverse Events  
DSMB – Data Safety Monitoring Board  
EKG – Electrocardiogram  
eCRF – electronic Case Report Form  
FDA – Food and Drug Administration  
FSS – Functional Status Scale  
GCMS – Gas Chromatography -Mass Spectrometry  
G-tube – Gastrostomy tube  
HA - Hyperammonemia  
HHS – Department of Health and Human Services  
HHS – Hyperinsulinism Hyperammonemia Syndrome  
HIPAA – Health Insurance Portability and Accountability Act  
ICH – International  Conference on Harmonization  
INR – International Normalized Ratio  
IRB – Institutional Review Board  
MMA – Methylmalonic Acidemia  
NAG – N-acetylglutamate  
NAGS – N-acetylglutamate  synthase  
NCG – N-carbamyl -L-glutamate, N -carbamylglutamate  
NG-tube – Nasogastri c tube  
NIH – National Institutes of Health  
PA – Propionic Acidemia  
PHI – Protected Health Information  
PI – Primary Investigator  
PID – Participant Identifier  
PLBO – Placebo  
PTT – Partial Thromboplastin Time  
REDCap – Research Electronic Data Capture  
SAE – Serious Adverse Event  
SOP – Standard Operating Procedures  
STD – Standard Therapy  
TCHC – The Children’s Hospital of Colorado  
StGr – Study Group  
UCD – Urea Cycle Disorder  
UCLA – University of California Los Angeles  
UHCMC – University Hospitals of Cleveland Medical Center  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 12 of 58 
 STUDY SYNOPSIS AND SCHEMA  
 
Protocol Number:  2894  
Protocol Title:  N-carbamylglutamate in the Treatment of Hyperammonemia: Accelerating the 
Resolution of Hyperammonemia and Clinical Recovery and Safety  
Study Chair:  Nicholas Ah Mew , MD  
Statistician:  Robert McCarter, ScD  
Consortium:  N-carbamylglutamate Consortium (NCGC)  
Participating Sites:  Boston Children’s Hospital (BCH), University Hospitals of Cleveland Medical 
Center (UHCMC), The Children’s Hospital of Colorado (CHCO), the Universi ty of 
California Los Angeles (UCLA), Children’s Hospital of Philadelphia (CHOP), Lucile 
Packard Children’s Hospital at Stanford (SU), Children’s National Hospital  
(Children’s National ), Children’s Hospital Pittsburgh (UPMC), and Mount Sinai 
Hospital (MSSM) . 
Activation Date:   July 2nd, 2012  
Sample Size:  36 patients experiencing approximately 114 hyperammonemia episodes across 
diagnoses (with approval to enroll up to 80 patients to allow for dropouts , losses to 
follow -up, and lower than expected incidence o f hyperammonemic episodes)  
Target Enrollment 
Period:  5 years  
Study Design:  Phase II  
Primary Study 
Objective:  The overall objective of this project is to determine whether treatment of acute 
hyperammonemia with N -carbamyl -L-glutamate (N -carbamylglutamate, NCG, 
Carglumic acid, Carbaglu) in propionic acidemia (PA), methylmalonic acidemia 
(MMA), late -onset CPS1 defic iency (CPSD) and late -onset Ornithine 
transcarbamylase deficiency (OTCD) accelerates the resolution of 
hyperammonemia.  
Study Population  
and Main Eligibility/ 
Exclusion Criteria:  Inclusion Criteria  
o Aged  older than 1 week with an established diagnosis of CPSD or OTCD 
(as follows):  
 Diagnosed with late -onset CPSD confirmed by detection of pathogenic 
mutation(s), and/or decreased (<20% of control) CPS enzyme activity 
in liver OR 
 Diagnosed with late -onset OT CD by detection of pathogenic OTC 
mutation, OR decreased (<20% of control) OTC enzyme activity in 
liver OR elevated urinary orotate (greater than 20 µM/mM creatinine) 
following allopurinol loading with absence of argininosuccinic acid  
 
 AND:  Subject or subj ect’s first-degree  relative had initial plasma 
ammonia level ≥100 mcmol/L >1 week of age  
 
OR 
 
o An established diagnosis of PA or MMA (as follows):  
 Diagnosed with PA by semi -quantitative urine organic acid analysis, 
defined as presence of elevated  methylcitri c acid and normal 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 13 of 58 
 methylmalonic acid levels and no evidence of biotin -related  disorders 
in the organic acid analysis OR 
 Diagnosed with MMA by semi -quantitative urine organic acid analysis, 
defined as elevation of methylmalonic acid and no evidence  of vitam in 
B12 dependent disorder on plasma amino acid analysis ( B12 
dependency is defined by documented B12 responsiveness ) 
 
 AND:  Subject or subject’s first-degree  relative had plasma ammonia 
level at any time ≥100 mcmol/L  
 
o Able to receive medications orally, by nasogastric (NG) -tube or by Gastric 
(G)-tube 
o No concomitant illness which would preclude safe participation as judged by 
the investigator  
o If post-menarcheal  must have a negative pregnancy test prior to  
administration of study drug at each episode  
o Signed in formed consent by the subject or the subject's legally acceptable 
representative  
 
Exclusion criteria  
o Administration of NCG within 7 days of participation in the study  
o Use of any other investigational drug, biologic, or therapy  
o Planned participation in any other clinical trial  
o Diagnosis of any medical condition causing hyperammonemia which is not 
PA, MMA, CPSD, OTCD  
o Any clinical or laboratory abnormality or medical condition that, at the 
discretion of the investigator, may put the subject at an additional ri sk by 
participating in this study  
o Had a liver transplant  
o Is pregnant  
o Is not expected to be compliant with the study  
 
Patients enrolled in the now-closed  long-term outcomes study being conducted in 
parallel are eligible to enroll in this study provided tha t all other inclusion and 
exclusion criteria are satisfied.  
Primary Outcome 
Measures:  Composite of the shortest of the time to reach an ammonia level <50 mcmol/L or time 
to discharge from the hospital after the first dose of NCG. Safety of NCG treatment 
as measured by serious adverse events, electrocardiogram test and laboratory blood 
tests 
Statistical 
Considerations 
(sample size and 
analysis plan):  Based on 2 -tailed testing assuming a type 1 error of 5% and using comparisons of 
treatment effects across episodes, a sample size of 36 patients, experiencing an 
average of <4 episodes each (total 114 episodes) would provide 80% power to 
detect hazard ratio at least as large as 1.7 favoring a higher average probability of 
the composite outcome in the NCG group . A sample size of 80 will allow for drop 
outs, losses to follow -up, and lower than expected incidence of hyperammonemic 
episodes.  
Sponsors (federal, 
state, foundation and 
industry support):  National Institutes of Health (NIH), Recordati Rare Diseases  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 14 of 58 
 1 INTRODUCTION  
 
 Background  1.1
1.1.1  The Urea Cycle  
The urea cycle consists of several biochemical steps required for the conversion of ammonia 
into urea (Figure). The first and rate -limiting step of the urea cycle is catalyzed by the 
mitochondrial enzyme, carbamyl  phosphate synthetase (CPS1), which converts ammonia, 
bicarbonate, and ATP into carbamyl phosphate. Subsequently, the enzyme ornithine 
transcarbamylase (OTC) conjugates ornithine and carbamyl  phosphate to form citrulline, which 
then continues through the r est of the urea cycle. CPS1 has as an essential allosteric enzyme, 
N-acetylglutamate , produced from the enzyme N -acetylglutamate  synthase.  
 
 
 
1.1.2  Carbamyl Phosphate Synthetase I Deficiency (CPSD)  
Carbamyl phosphate synthetase I is the first and rate -limiting step of the urea cycle  and 
converts ammonia, bicarbonate, and adenosine triphosphate (ATP) into carbamyl phosphate. 
Mutations which completely abolish CPS activity, eliminate flux through this step, and lead to 
hyperammonemia. However, mutations resulting in reduced but not abolished CPS enzyme 
function may result in an attenuated form of hyperammonemia, characterized by a later 
presentation, plasma ammonia better amenable to dietary and pharmacotherapy or fewer 
admissions for hyperammonemia. Nevertheless, episodes of hyperammonemia may still be life-
threatening , and if untreated, may result in coma or death. Clinical features of hyperammonemia 
may also include encephalopathy, brain edema, tachypnea, lethargy, vomiting, hypotonia, and 
hypothermia.  
 
1.1.3  Ornithine  Transcarbamylase Deficiency (OTCD)  
Ornithine transcarbamylase (OTC) conjugates carbamyl  phosphate and ornithine to form 
citrulline. Deficiency of the OTC enzyme results in hyperammonemia  and may result in 
encephalopathy, brain edema, tachypnea, lethargy, vomiting, hypotonia, hypothermia, and if 
untreated, coma and/or death. The OTC gene is located on the X -chromosome, thus males 
have only one copy of the OTC gene, whereas females have two copies, but due to lyonization 
have only one active copy per cell. T he X -chromosome in each cell that is inactivated is 

Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 15 of 58 
 determined randomly and prenatally, at an early embryological stage. A partial deficiency of 
OTC may be observed in hemizygous males only if a mutation in the OTC gene is hypomorphic. 
However, in affected  females, a partial deficiency is typically only observed with mutations that 
entirely abolish OTC activity. This is because due to lyonization, affected females have two 
populations of hepatocytes – those that express the mutant OTC allele, and those that  express 
the normal allele.  
 
1.1.4  Propionic Acidemia (PA)  
Propionic acidemia (PA) is caused by a complete  or partial deficiency of the enzyme, propionyl -
CoA carboxylase, or a defect in the utilization or salvage of its cofactor, biotin. In the neonatal 
period, this condition can present with lethargy, poor feeding, vomiting, ketoacidosis, and 
hyperammonemia, and may result in death if not treated appropriately. Ammonia can reach 
extremely high levels, approaching those seen in patients with urea cycle disorders (ref).  
 
1.1.5  Methylmalonic Acidemia (MMA)  
Methylmalonic acidemia/aciduria (MMA) is caused by a complete  or partial deficiency of the 
enzyme methylmalonyl -CoA mutase, a defect in the transport or synthesis of its cofactor, 
adenosyl -cobalamin , or deficiency of th e enzyme methylmalonyl -CoA epimerase. In the 
neonatal period, the disease can present with lethargy, vomiting, hypotonia, hypothermia, 
respiratory distress, severe ketoacidosis, and hyperammonemia, and can result in death if not 
appropriately treated. Hype rammonemia also occurs in methylmalonic acidemia, in particular in 
the neonatal period, and like in PA, can approach levels seen in patients with urea cycle 
disorders.  
 
1.1.6  Mechanism of Hyperammonemia in PA and MMA  
Hyperammonemia in PA and MMA are thought to r esult from the inhibition of the N -
acetylglutamate  (NAG) synthase reaction. This may be either the result of direct competitive 
inhibition of the NAG synthase reaction by the organic acid, from decreased availability of 
acetyl -Coenzyme A or from Coenzyme A  depletion (ref). Any of these mechanism  lead to 
decreased mitochondrial concentration of NAG. Because NAG is the essential allosteric 
cofactor  to carbamylphosphate  synthase (CPS1) reaction (the first step of the urea cycle), a 
decrease in NAG concentratio n leads to decreased flux through the CPS1 reaction and results 
in hyperammonemia.  
 
1.1.7  Current Therapies for Hyperammonemia  
Very few drugs to treat hyperammonemia have been developed and brought to market. Dietary 
protein restriction and administration of al ternate pathway acylating agents are the current 
primary treatments, but they frequently fail to avert brain damage. Current alternate pathway 
therapies remove excess nitrogen stoichiometrically, eliminating a fixed number of nitrogen 
atoms (1 or 2) for ev ery molecule of drug administered, reactions, which require the adequate  
liver function to be effective.  
   
Orthotopic liver transplantation cures hyperammonemia, but organ availability has been limited 
and the procedure is highly invasive and requires li fe-long immunosuppression.  
 
Since hyperammonemia is critical in the pathophysiology of screenable disorders such as urea 
cycle defects and possibly organic acidemias, which are currently, or will be in the near future 
detectable by expanded newborn screen ing, developing new innovative treatments for these 
disorders is essential if early diagnosis is to change the natural course of these conditions.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 16 of 58 
  
 
 Study Rationale   1.2
As described above, current drug therapy for inherited hyperammonemia relies mainly on the 
activation of alternate pathways for nitrogen elimination. In contrast, N -carbamylglutamate (NCG), a 
stable analog of N -acetylglutamate , catalytically stimulates the urea cycle, thus converting many more 
molecules of ammonia to urea with a relatively s mall dose of the drug. This represents a paradigm 
shift in the medical  treatment of hyperammonemia.  
 
A drug that could repair or stimulate a dysfunctional urea cycle would have several advantages over 
current therapy. First, it would intervene through the  normal pathway of ureagenesis, which is 
catalytic rather than stoichiometric. Second, it may not need to replace current treatment but would be 
complementary to it. Third, the ability to stimulate residual ureagenesis could benefit many conditions 
that ca use hyperammonemia, not just a single disorder. Enhancement of residual ureagenesis 
capacity in patients with hyperammonemia would markedly alter the natural disease course resulting 
in a manageable phenotype and better clinical outcome.  
 
Our recent studie s show that ureagenesis is augmented by NCG in healthy individuals and in more 
than half of all individuals with inborn errors that were tested.  
 
The eligibility for the studies in this study specifically includes severe PA and MMA and “milder” 
CPSD and OT CD, which may appear paradoxical. However, the rationale for these selection criteria 
is based on the different mechanism(s) of action in these disorders. Significant hyperammonemia in 
PA or MMA is usually seen only in the most severely affected patients w ho present as newborns. 
Patients with hypomorphic alleles have milder disease and are unlikely to have serious 
hyperammonemia.72 In severely affected patients with PA and MMA, NCG works to alleviate 
deficiency of NAG created by the inhibition of NAGS by th e mitochondrial accumulation of propionyl -
CoA, hence, the more profound the NAG deficiency, the more robust the NCG effect. In CPSD and 
OTCD however, the putative effect of NCG relies on stimulating residual CPS1 or OTC activity. 
Indeed, when these enzymes  are totally absent, no amount of NCG would help, hence, the need to 
enroll patients with partial rather than complete enzyme deficiencies.  
 
If the proposed studies show that the use of NCG is effective in enhancing or completely restoring 
ureagenesis in p atients with PA, MMA, CPSD and/or OTCD, they can be treated long -term with this 
therapeutic agent either during acute episodes or chronically. Carbaglu is FDA -approved (03 -2010). 
Thus, responsive participants could receive this medication off -label if thei r physician obtains a single 
patient IND. There can be an important direct benefit for these participants. If the underlying 
hypothesis is correct, this study could improve the medical condition of some or all of the patients, 
also preventing  life-threaten ing events in those who respond.  
 
The study will provide the first reliable information of whether NCG could potentially reduce the 
hyperammonemia associated with the 4 disorders to be studied. Such knowledge could provide a 
new treatment for some patient s with hyperammonemia. In addition, the information gained could 
also be relevant to better understanding the regulation of the urea cycle, which may impact also the 
treatment  of hyperammonemia due to generalized liver disease or other causes.  
 
This emergi ng concept posits that NCG will be effective as an adjunct treatment for hyperammonemia 
in several conditions. A few case reports provide anecdotal evidence for the effectiveness of NCG in 
reversing hyperammonemia in propionic acidemia (PA) and methylmalon ic acidemia (MMA)  17-22. 
Although  these observations may be factually correct, they do not represent credible scientific 
evidence and are unlikely to be accepted by regulatory agencies. The studies proposed herein, are 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 17 of 58 
 placebo -controlled , randomized, and b linded addressing this question using multiple true and 
surrogate endpoints, increasing scientific reliability.   
 
 Study Treatment: N -carbamyl -L-glutamate (NCG)  1.3
N-carbamylglutamate, Carglumic acid, and Carbaglu are synonyms for the study treatment, N -
carba myl-L-glutamate (NCG).  
 
N-carbamyl -L-glutamate (NCG) has recently been found to have virtually curative of a urea cycle 
defect, N -acetylglutamate  synthase (NAGS) deficiency (FDA IND# 68,185). In this disorder, treatment 
with NCG alone normalizes ureagenesis, blood ammonia,  and glutamine levels, allows normal protein 
tolerance, and restores health. Knowledge from the study of NCG in inborn errors  could be applied to 
acquired hyperammonemia, specifically in patients with propionic acidemia (PA) and methylmalonic 
acidemia (MMA), to improve neurodevelopmental outcomes and reduce nitrogen load.  
 
1.3.1  Preclinical Profile  
Carbaglu® is synthesized by Synth -Innove and was confirmed to activate CPS I in vitro. 
Labeled NCG injected into mice can be detected in the liver.  
Toxicology studies in rats, at doses of up to 1000 mg/kg did not show any neurobehavioral, 
neurovegetative , neurotoxic or psychotropic effects nor  any effects on body temperature. 
Respiratory function, including respiratory rate, peak respiratory and inspiratory flows, 
inspiration and expiration time, tidal volume and airway resistance also showed no statistically 
significant change.  
 
In isolated c anine Purkinje fibers, there was no statistically significant effect on action potential 
parameters, and no dearly  depolarization was observed at any concentration. Additionally NCG 
at concentrations up to 0.1 mM had no effect on action potential duration.  
 
Toxicology studies on the cardiovascular system in dogs showed no change in blood pressure, 
heart rate and cardiac conduction times including QT interval and QTc after administration of up 
to 1000 mg/kg of Carbaglu.  
 
Carbaglu was administered enterally once up to 2806 mg/kg or intravenously up to 238.6mg/kg, 
in Sprague -Dawley rats, and no mortality was observed.  
 
No clastogenic activity was found in a study with human lymphocytes, and the micronucleus test 
in rats was negative. The impurity hydantoin -5-propionic acid demonstrated clastogenic activity 
at concentrations > 2500 µg/ml. The quality profile of Carbaglu is less than 0.1% hydantoin -5-
propionic acid. NCG does not seem to affect male or female fertility.  
 
1.3.1.1  Pediatric Animal Studies  
In newbor n rats, NCG given at 2000 mg/kg/day was lethal to all pups between 2 -14 days. At 
1000 mg/kg/d, orange colored feces, a slight reduction of body weight gain, and a 
decreased thymus weight were observed. At doses of <500 mg/kg/d, NCG was well 
tolerated, and no adverse effects were observed.  
 
NCG was also administered to 4 -week old Sprague -Dawley rats daily for 6 months at doses 
of 500 or 1000 mg/kg/d. At 1000 mg/kg/d, ptyalism (excess salivation) was the only adverse 
effect observed.  
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 18 of 58 
 1.3.2  Clinical Profile  
 
1.3.2.1 Carbaglu in Treatment of NAG Synthase Deficiency  
Carbaglu corrects the biochemical defect and normalizes all biochemical parameters, 
including ammonia, in patients with a primary deficiency of NAG, as observed in NAG 
Synthase (NAGS) deficiency. Ret rospective data from 13 patients with NAGS who were 
treated for acute hyperammonemia were collected by Orphan Europe. Mean plasma 
ammonia for these patients at initial presentation, as well as each day following Carbaglu 
administration, is shown in Figure 1, below:  
 
Figure 1. Mean ammonia vs. time in n=13 subjects with NAGS deficiency receiving 
Carbaglu  
 
 
1.3.2.2 Carbaglu in Secondary Deficiencies of NAG  
Several publications have pointed out the potential of NCG as a therapeutic adjunct to the 
treatment o f hyperammonemia in secondary deficiencies of NAG (i.e., not resulting from 
NAGS deficiency). All these reports were uncontrolled case reports or case series10-13,15,20. 
 
Our first project was initially funded for 34 months from 8/5/2008 through 5/ 31/2011. The 
original specific aims were: 1) To determine whether 3 -day treatment with NCG improves or 
restores ureagenesis in patients with NAGS deficiency, Carbamyl phosphate synthase 
(CPSD), PA, MMA and hyperinsulinism and hyperammonemia syndrome (HHS),  and 2) To 
evaluate the safety of short -term (3 -day) treatment with NCG. The accomplishments thus far 
indicate that 3 -day treatment with NCG:  
 Normalizes ureagenesis rate, plasma ammonia, glutamine and urea in NAGS 
deficiency10,21  
 Enhances ureagenesis and reduces plasma ammonia and glutamine levels in PA9 
 Improves ureagenesis and decreases plasma ammonia and glutamine in some 
patients with CPSD  
 Improves ureagenesis in some patients with HHS  

Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 19 of 58 
  Is safe at the prescribed dose of 100/mg/k/d or 2.2 g/m2/d 
In addition, we found that a single dose of NCG  rapidly augments ureagenesis rate in 
healthy adults8. 
1.3.2.3 Carbaglu in PA and MMA  
As described above, limited case reports have suggested the use of NCG in PA and MMA9-
14.  
 
We applied the same study design as described above to investigate the effect of NCG in 
severe PA and MMA. These patients usually present as newborns and have marked and 
recurrent hyperammonemia. As of the time of this reporting, we completed studies of 7 
patients with PA and 1 patient with MMA. We specifically wanted to determine whether NCG 
reduces plasma levels of ammonia and glutamine and increases ureagenesis rate, even 
though plasma glutamine levels are typically not elevated in PA.   
 
Results from lo ngitudinal mixed effects linear regression (Figure 2) show that peak 
[13C]urea increased following 3 days of NCG treatment (from 2.2 μM to 3.8 μM p<0.0005). 
There were corresponding decreases in mean plasma ammonia (59 to 43 μM p<0.0005) 
and glutamine (552  to 331 μM p<0.0005). This study demonstrated conclusively that NCG 
enhances ureagenesis and reduces plasma ammonia and glutamine concentrations in 
patients with PA. We obtained similar results in the patient with MMA, thus, this protocol 
represents a syst ematic approach to validating  these findings a controlled clinical trial.  
 
Figure 2. [13C] -urea before (pre -NCG) and after (post -NCG) a 3 -d NCG treatment in 7 
patients with PA9 
 
 
1.3.3  Carbaglu Formulation and Dosage  
Chemical Composition:  N -carbamoyl -L-glutamic acid (NCG)  
 

Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 20 of 58 
 Study drug will be prepared for administration accord ing to the package insert. Briefly, study 
drug tablets will be dispersed in water and ingested or administered immediately via nasogastric 
or gastrostomy tube.  
 
The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg. The doses are to be 
divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy 
tube. Standard care will prevail when choosing the mode of drug administration.  
 
1.3.4  Safety and Side Effects of Carbaglu  
The safety of Carbaglu for the treatmen t of hyperammonemia due to NAGS deficiency was 
evaluated in a retrospective review of 23 patients (14 males and 9 females) (Carbaglu 
[prescribing information]. Orphan Europe; 2010). The most common adverse reactions 
(occurring in >13% of patients), regardl ess of causality, were infections, vomiting, abdominal 
pain, pyrexia, tonsilitis , anemia, ear infection, diarrhea, nasopharyngitis,  and headache.   
 
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 21 of 58 
 2 OBJECTIVES  
 
To determine whether NCG treatment of acute hyperammonemia in severe, neonatal -onset PA and 
MMA, partial CPSD, and OTCD is efficacious  and whether it is safe.  
 
 Assess Efficacy of NCG Treatment   2.1
The objective of this study is to assess whether NCG is efficacious in treating hyperammonemia and 
improving the following outcomes:  
 The primary efficacy outcome of this study is the resolution of the ammonia levels or earlier 
discharge following the hyperammonemia episode(s).  
 The secondary efficacy outcomes of  this study include the Functional Status Scale, 
measured daily during each hyperammonemic episode, and the length of hospitalization.  
 
This goal will be realized by randomizing each hyperammonemic episode from every subject to  NCG 
plus standard treatment  (NCG -STD) versus placebo plus standard treatment (PLBO -STD) and 
subsequently gauging response with the primary outcome of plasma ammonia levels, in addition to 
the Functional Status Scale and the length of hospitalization.  
 
 Safety  2.2
The primary safety outco me of the study will be the rate of Serious Adverse Events (SAEs) during 
study episodes defined in this study as death or substantial prolongation of hospitalization, as 
patients are hospitalized as part of having a qualifying hyperammonemia episode. Safet y tests 
consisting of complete blood count (CBC), liver and kidney function tests, coagulation profile 
(PTT/INR) will be performed before treatment, on the third day of treatment,  just prior to episode 
treatment completion of NCG and thirty days (up to si x months) after the last study dose. Patients in a 
hyperammonemia crisis frequently experience transient anemia once appropriately hydrated during 
an emergency room visit. In order to monitor the transient anemia, in addition to collecting CBC’s, if a 
patient receives a blood  transfusion during hospitalization this information will also be collected. An 
EKG test will be performed before treatment and between days 3 -5 of treatment or before discharge if 
earlier.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 22 of 58 
 3 STUDY DESIGN  
 
 Overview of Study Design  3.1
This will be a double -blinded, placebo controlled randomized clinical trial to evaluate the efficacy of 
NCG in the treatment of two organic acidemias (severe PA and MMA), and two urea -cycle disorders 
(late-onset CPSD and OTCD). Figure 3 summarizes the desi gn of the proposed trial.  
 
Figure 3. Study Overview Diagram  
 
 
Protocol Overview  
 Eligibility  – Briefly, subjects (a) aged >1 week with verified diagnosis of CPSD or OTCD or 
(b) subjects of any age with verified diagnosis of PA or MMA and ammonia level 
≥70mcmol/L. All subjects ( or a first-degree  relative) must have had a recorded plasma 
ammonia ≥100 mcmol/L  and must have presented initially at >1 week of age for CPSD or 
OTCD. Subjects must not be pregnant. A complete listing of eligibility criteria is incl uded in 
Section 4 (Study Population).  
 Enrollment  – Informed consent from the participant  or one  parent or legal guardian.  
 Randomization  –  At each hyperammonemic episode, participants will be randomized to 
either placebo plus standard therapy (PLBO -STD) o r NCG plus standard therapy (NCG -
STD) at  a dose of 150 mg/kg/ day or 3.3  g/m2/day for patients >15 kg, divided into 2 equal 
doses and administered enterally by nasogastric or gastrostomy tube or by oral syringe.  
 Study Treatment  – The NCG/PLBO dose will be administered for metabolic 
decompensation for 7 days or until discharge, whichever is shorter.  
 Concomitant Standard Treatment  – Participants will continue receiving standard treatment 
which may include intravenous glucose (and insulin if required), L -carnitine dosing and/or 
dialysis. Ammonia scavengers may only be administered in patients with urea cycle 
disorders.  

Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 23 of 58 
  Laboratory  Measurements  – Plasma ammonia testing should be performed as clinically 
indicated, including checking the level at admission and a t least every 6 -12 hours for the first 
48 hours and every day thereafter if the previous level was ≥50 mcmol/L, for a total of 7 
days or until discharge, whichever is shorter. Plasma amino acids should also be checked 
as clinically indicated at admission a nd at least every 2 days thereafter, if ammonia levels 
are measured. Safety laboratory assessments including complete blood cell count, liver and 
kidney function tests, amylase and lipase testing, as well as a coagulation profile (if clinically 
indicated) will be done at the time of initial admission, at 3 -5 days, at 6 -7 days or at 
discharge, whichever is shorter.  
 Electrocardiogram (EKG) Test  – At each episode, participants will have an EKG at 
admission and repeated on day 3 -5 of treatment (48 hours followi ng the initial drug 
administration, before discharge if earlier) to check for cardiac toxicity.   
 Functional Scale Score (FSS)  – Determined for each episode at admission and every day 
of hospitalization for a total of 7 days or until discharge, whichever i s shorter.  
 Recurrent Episodes  – Each subsequent admission for metabolic decompensation will 
follow the same above procedure but has to occur at least 7 days after the last discharge to 
guarantee study drug wash out before the next administration should patient have received 
study drug .  
  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 24 of 58 
 4 STUDY POPULATION  
 
Patients enrolled in the long -term outcomes study being conducted in parallel are eligible to enroll in 
this study when the long -term outcomes study closes, provided that all other inclusion and exclusion 
criteria are satisfied.  
 
 Inclusion Criteria  4.1
o Aged  older than 1 week with an established diagnosis of CPSD or OTCD (as follows):  
 Diagnosed with late -onset CPSD confirmed by detection of pathogenic mutation(s), 
and/or decreased (<20% of control) CPS enzyme activity in liver OR 
 Diagn osed with late -onset OTCD by detection of pathogenic OTC mutation, OR 
decreased (<20% of control) OTC enzyme activity in liver OR elevated urinary 
orotate (greater than 20 µM/mM) following allopurinol loading with absence of 
argininosuccinic acid  
 
 AND:  Subject or subject’s first-degree  relative had plasma ammonia level 
≥100 mcmol/L >1 week of age  
 
OR 
 
o An established diagnosis of PA or MMA (as follows):  
 Diagnosed with PA by semi -quantitative urine organic acid analysis, defined as 
presence of elevated  methylcitric  acid and normal methylmalonic acid levels and 
no evidence of biotin -related  disorders in the organic acid analysis OR 
 Diagnosed with MMA by semi -quantitative urine organic acid analysis, defined as 
elevation of methylmalonic acid and no eviden ce of vitamin B12 dependent 
disorder on plasma amino acid analysis  (B12 dependency is defined by 
documented B12 responsiveness)  
 
 AND:  Subject or subject’s first-degree  relative had plasma ammonia level at 
any time ≥100 mcmol/L  
 
o Able to receive medications orally, by nasogastric (NG) -tube or by gastric (G) -tube 
o No concomitant illness which would preclude safe participation as judged by the 
investigator  
o If post-menarcheal  must have a negative pregnancy test prior to administration of study 
drug at each episod e 
o Signed informed consent by the subject or the subject's legally acceptable 
representative  
 
 Exclusion Criteria  4.2
o Administration of NCG within 7 days of participation in the study  
o Use of any other investigational drug, biologic, or therapy.  
o Planned participation in any other clinical trial  
o Diagnosis of any medical condition causing hyperammonemia that is not PA or MMA. 
CPSD or OTCD. Other urea cycle disorders will be excluded from this study.  
o Any clinical or laboratory abnormality or medical conditio n that, at the discretion of the 
investigator, may put the subject at an additional risk by participating in this study  
o Has had a liver transplant  
o Is not expected to be compliant with this study in terms of returning to site for 
subsequent episodes of hyp erammonemia crises  
Is pregnant  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 25 of 58 
 5 STUDY PROCEDURES  
 
 Screening of Potential Subjects  5.1
Prior to enrollment, patients must be deemed by the site PI, or his assigned surrogate, to meet 
eligibility criteria.  
 
5.1.1  Confirmation of diagnosis of PA, MMA, CPSD or OTCD  
5.1.1.1  Diagnosis of PA or MMA  
Results from the subject’s urine organic acid analysis, performed via semi -quantitative 
methods by gas chromatography –mass spectrometry (GCMS), should be reviewed. Patients 
who do not meet these laboratory diagnostic criteria  will not be enrolled.  
5.1.1.1.1 Laboratory Diagnostic Criteria for PA  
1) Elevation of methylcitric  acid and propionylglycine  
2) No elevation in methylmalonic acid  
3) No evidence of biotin -related  disorders  
5.1.1.1.2 Laboratory Diagnostic Criteria for MMA  
1) Elevation of methylmalonic acid  
2) No elevation of homocysteine, total homocysteine, or homocysteine -cysteine 
disulfide by plasma amino acid analysis  
3) No response to 1 mg IM hydroxocobalamin injections  
5.1.1.1.3 Laboratory Diagnostic Criteria for CPSD  
 Detect ion of pathogenic CPS1 mutation(s) OR 
 Decreased (<20% of control) CPS enzyme activity in liver  
5.1.1.1.4 Laboratory Diagnostic Criteria for OTCD  
 Detection of pathogenic OTC mutation OR 
 Decreased (<20% of control) OTC enzyme activity in liver OR 
 Elevated ur inary orotate (greater than 20 µM/mM) following allopurinol loading, 
with absence of argininosuccinic acid on plasma amino acid analysis  
 
5.1.1.2  Documentation of Hyperammonemia  
1) The subject (or subject’s first -degree relative) should have a previously 
documented ammonia level at any time of ≥100 mcmol/L  
2) If diagnosed with CPSD or OTCD (as per above), initial hyperammonemia 
should have occurred >1 week of age  
 
In some cases, a subject may have been diagnosed prenatally, or before the manifestation 
of symp toms, because of previously -identified affected family member. As a result, the 
subject may have been treated prospectively  and averted any early hyperammonemic 
events. In such cases, the previously -identified first -degree relative must meet the above 
criteria instead.  
 
 Informed Consent Procedures  5.2
Participants will be recruited from all participating sites and their metabolic services. Ideally, patients 
will be recruited to this study during periods of clinical and metabolic stability, rather than at the ti me 
of presentation of acute illness or hyperammonemia.  Whenever possible, the participants (or 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 26 of 58 
 guardians) will be given a copy of the consent form for review, several days before the formal 
informed consent process takes place.  
 
For participants who can provide informed consent:  
The licensed physician investigator  will meet with the potential study participant to describe the study. 
Patients will be brought to a private, quiet room where the benefits and risk of study will be explained 
thoroughly, and any  questions will be answered. The investigator will then give the patient time to 
read the consent form and consider participation. The investigator will return to answer questions, 
ensure that the patient understands the information provided, and obtain in formed consent.  
  
For participants unable to provide informed consent who arrive with parents/guardians:   
The site PI will meet with the parent(s) or guardian(s) to describe the study. Parents will be brought to 
a private, quiet room where the benefits and  risks of the study will be explained thoroughly, and any 
questions will be answered. The investigator will then give the parent(s) time to read the consent form 
and consider participation.  The investigator will return to answer questions, ensure that the  
parent/guardian understands the information provided, and obtain informed consent.  
 
For participants unable to provide informed consent arriving without parents/guardians:   
Some of these patients may be transferred directly from another institution with out parents or 
guardians. Patients’ families will be first contacted by phone by clinical personnel to discuss the 
possibility of participating in a clinical trial. Should they be interested, informed consent will be 
obtained by the site PI by telephone be fore the study can begin. The investigator will speak with the 
parent/guardian by phone, and provide them with a copy of the consent form (e.g., by fax, e -mail). 
When the parent/guardian receives the consent form, it will be immediately signed and sent/fax ed 
back to the investigator. No research -related activities will occur until a signed hard copy of the 
consent form has been received by the investigator.     
 
For participants who are being recruited during a period of clinical and metabolic stability:  
Whenever possible, patients will be  recruited to participate during periods of clinical and metabolic 
stability. The site PI  will meet with these patients (and their families, if applicable) following their 
routine clinical visits to discuss study partici pation, to answer questions, to ensure that all information 
provided is understood, and to obtain informed consent. Patients who are not scheduled for a routine  
clinical visit within the next 3 months will be contacted by phone by clinical personnel to dis cuss the 
possibility of participating in a clinical trial. Should they be interested, informed consent will be 
obtained by the site PI by telephone. The investigator will speak with the patient or parent/guardian by 
phone, and provide them with a copy of t he consent form (e.g., by fax, e -mail, or post). When the 
patient or parent/guardian receives the consent form, it will be signed and returned to the investigator. 
No research -related activities will occur until a signed hard copy (original or facsimile) o f the consent 
form has been received by the investigator.     
  
Informed consent documents will be available in English. If patients or their parents/guardians are 
only fluent in another language, and the site has a standard operating procedure for informe d consent 
in that language (such as an on -call interpreter and if available abbreviated consent form in 
respective language) and the site IRB has approved the process for this study in advance, non -
English speaking patients,  and parents/guardians will also  be included.  
 
 Retention Procedures  5.3
Every effort will be made to identify patients who have enrolled in this study at their next presentation 
to the emergency department or another medical facility.  
 At the time of enrollment, patient families will be provi ded with a card, indicating that they 
are participating in an investigational drug trial, to be presented to hospital staff at 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 27 of 58 
 subsequent episodes of illness. They will also be reminded to inform the on -call genetics or 
metabolism attending physician of th eir participation in this trial.  
 The last note from the treating genetics and/or metabolism physician will indicate in the plan, 
or in an addendum, that the patient is participating in a clinical investigational drug trial  
 The patient charts will be flagge d, if possible, indicating that the patient is participating in a 
clinical investigational drug trial  
 Duration of Study and Visit Schedule  5.4
5.4.1  Hyperammonemia Episodes  
At any time after the initial enrollment, participants may present to the hospital with PA -, MMA -, 
CPSD - or OTCD - associated symptoms (see Sections 1.1.2 -1.1.5). Indicated clinically, the 
plasma ammonia level should be verified.  
 Subjects are not eligible to receive study drug if they have received NCG or study drug 
any time in the preceding 7 day s. 
 If plasma ammonia is ≥70 mcmol/L at presentation (confirmed on site) or during a 
hospitalization for an acute decompensation, participants should receive the study drug. 
The time from an episode - qualifying ammonia level to randomization should not be 
longer than a maximum of 4 hours.  
 
5.4.1.1 Random Group Assignment  
At each hyperammonemia episode, subjects will be randomized to a treatment arm. 
Randomization will be performed online using a stored, pre -generated, encrypted 
randomization schedule created by the CNMC Division of Biostatistics and Study 
Methodology. To complete the process, the Site Pharmacy will simultaneously receive an 
automated notification of the assignment to enable them to prepare the correct prescription 
for the participant. The time from randomization to study treatment administration should be 
as brief as possible and no longer than a maximum of 6 hours.  
 
5.4.1.2 Concurrent with Randomization  
Pre-Treatment  
1. Indicated clinically, a blood  sample will be drawn for plasma ammonia and amino 
acid analysis. All patients are expected to have clinically indicated vascular access. If 
vascular access is inadequate, blood will be drawn by venipuncture. All ammonia 
levels measured up to 24 hours prio r to first treatment administration will be 
recorded. Ammonia levels measured >24 hours prior to first treatment administration 
will not be recorded in this study.  
2. Laboratory safety assessments: complete blood count (CBC), liver function tests 
(LFT), renal  function test (RFT), amylase and lipase. If indicated clinically, a 
coagulation profile (PTT and INR) should also be done. A pregnancy test is required 
(if applicable).  
3. Electrocardiogram (EKG) test  
4. Functional Status Scale (FSS) assessment  
 
 
 
 
 
Table 1. Ho spitalization Study Procedures  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 28 of 58 
  Day 1  Day 2  Day 3  Day 4  Day 5  Day 6  Day 7  Day 30  
(≤6 Months)  
Time (hours)  0 Post 
Dialysis 6 12 18 24 36 48 60 72 84 96 108 120 132 144 156  
Confirm 
Eligibility  X                  
Pregnancy 
Testb X                  
Randomization  X                  
Plasma 
Ammonia 
Levelc  X (X) X X Xd X X X  Xf  Xf  Xf  Xf   
Plasma Amino 
Acidsc X (X)    X    Xg    Xg     
Safety Labsc X       Xh X  
EKG Testi X       Xi    
Functional 
Status Scalec X    X  X  X  X  X  X  X  
Concomitant 
Medications 
Log     X  X  X  X  X  X  X  
Adverse 
Events Log      X  X  X  X  X  X  X  
Study Drug 
(NCG or 
PLBO)  X   X  X X X X X X X X X X X X  
Treatment 
Administration 
Log X   X  X X X X X X X X X X X X  
Blood 
Transfusion 
Log X   X  X X X X X X X X X X X X  
NCG=N -carbamylglutamate; PLBO=Placebo  
a  Suggested timeline to be followed for 7 days, or until discharge if discharged prior to 7 days of drug administration  
b  For women of childbearing potential only. A serum pregnancy test will be performed in the event of a positive or equivocal ur ine pregnancy 
test result, or if the patient is anuric  
c  Allowable windows for day 3 (days 3 -5) and day 7 ( days 6 -7), unless otherwise indicated  
d  Plasma ammonia should be drawn as frequently as clinically indicated, for example, every 6 hours during the first 24-hour window if the 
patient  has a central or peripheral venous catheter.  
e  Only to be drawn if dia lysis is performed. Blood draws should be performed immediately upon termination of hemodialysis or hemofiltration, 
even if the regular time -point labs have been drawn.  
f  Plasma ammonia should be drawn as frequently as clinically indicated, for example, a fter 48 hours, follow -up ammonia should be obtained 
if the prior measurement was ≥50 mcmol/L  
g  Amino acids should be drawn as frequently as clinically indicated, for example, obtained only if ammonia also obtained (see f ) 
h  Safety Lab blood draw to be o btained on day 6 -7, or if discharged <7d, within 24h prior to discharge  
i EKG should be done before treatment begins and repeated once between Days 3 -5 or before discharge  
 
 
5.4.1.3 Post -Randomization  
Day 1  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 29 of 58 
 1. As per their assignment, the participant will be started on NCG (150 mg/kg/day 
for patients ≤15 kg or 3.3  g/m2/day for patients >15 kg in two divided doses) OR 
PLBO ( three -quarters tablet/kg/d for patients ≤15 kg or 16.5 tablets/m2/day for 
patients >15 kg, in two divided doses) to be administered through  a nasogastric 
tube, or if not available, by oral syringe, as described in Section 6.1. The 
participant will also continue to receive standard therapy.  
2. Following the first drug administration, the subsequent drug administration should 
be given between 6 an d 12 hours after the first dose, at a standard drug 
administration time for the site. All subsequent doses should be given every 12 
hours.  
3. Indicated clinically, plasma ammonia testing will be performed every 6 hours 
following study drug administration if t he patient has a central or peripheral 
catheter. In all other cases, plasma ammonia testing will be performed every 12 
hours, as indicated clinically.  
4. Clinical monitoring FSS  
5. Treatment administration log, concomitant medications log, blood transfusion log,  
and adverse events log will be completed daily  
  
Day 2  
1. NCG/PLBO Rx. & Standard Rx every 12 hours.  
2. Plasma ammonia every 12 hours (as indicated clinically)  
3. Amino acids (as indicated clinically)  
4. Clinical monitoring FSS  
5. Treatment administration log, concomitant medications log, blood transfusion log, 
and adverse events log will be completed daily  
 
Day 3 (if not yet discharged)  
1. NCG/PLBO Rx. & Standard Rx every 12 hours.  
2. Plasma ammonia (as indicated clinically)  
3. Safety labs should be performed between d ays 3 - 5 
4. EKG test should be performed between days 3 -5 
5. Clinical monitoring FSS  
6. Treatment administration log, concomitant medications log, blood transfusion log, 
and adverse events log will be completed daily  
 
Day 4 (if not yet discharged)  
1. NCG/PLBO Rx. & S tandard Rx every 12 hours.  
2. Plasma ammonia  (as indicated clinically)  
3. Amino acids (as indicated clinically)  
4. Clinical monitoring FSS  
5. Treatment administration log, concomitant medications log, blood transfusion log, 
and adverse events log will be completed da ily 
 
Day 5 (if not yet discharged)  
1. NCG/PLBO Rx. & Standard Rx every 12 hours.  
2. Plasma ammonia (as indicated clinically)  
3. Clinical monitoring FSS  
4. Treatment administration log, concomitant medications log, blood transfusion log, 
and adverse events log will be completed daily  
 
Day 6 (if not yet discharged)  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 30 of 58 
 1. NCG/PLBO Rx. & Standard Rx every 12 hours.  
2. Plasma ammonia (as indicated clinically)  
3. Safety labs should be performed between days 6 – 7 
4. EKG test should be performed between days 6 -7 (if not done already between  
days 3 -5) 
5. Amino acids (as indicated clinically)  
6. Clinical monitoring FSS  
7. Treatment administration log, concomitant medications log, blood transfusion log, 
and adverse events log will be completed daily  
 
Day 7 (if not yet discharged)  
1. NCG/PLBO Rx. & Standard  Rx. 
2. Plasma ammonia (as indicated clinically)  
3. Safety labs if not done on Day 6  
4. EKG if not already done  
5. Clinical monitoring FSS  
6. Treatment administration log, concomitant medications log, blood transfusion log, 
and adverse events log will be completed daily  
 
 Day 8 (if not yet discharged)  
1. The final  dose of NCG/PLBO Rx. & Standard Rx.  
2. Plasma ammonia (as indicated clinically)  
3. Treatment administration log, concomitant medications log, blood transfusions 
log and adverse events log will be completed a final time.  
 
5.4.1.4 Discharge Procedures  
If still on NCG/PLBO, the subjects will be discontinued from the study drug at the time of 
discharge from the hospital.  
 
We will contact subjects or their families to collect any adverse events that occurred in the 
72 hours f ollowing episode treatment completion.  
 
 
 Study Assessments  5.5
5.5.1  Laboratory Tests  
 Plasma ammonia (as indicated clinically)  
 Plasma amino acids (as indicated clinically)  
 Complete blood cell count  
o White blood cells and differential  
o Platelets  
o Hemoglobin  
o Hematocrit  
 Liver function tests  
o ALT (Alanine Aminotransferase)  
o AST (Aspartate Aminotransferase)  
o Alkaline phosphatase  
o Direct bilirubin  
o Total bilirubin  
o Albumin  
o Total protein  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 31 of 58 
  Kidney function tests  
o Blood urea nitrogen  
o Creatinine  
 Amylase and lipase  
o Amylase  
o Lipase  
 Coagulat ion profile (as indicated clinically)  
o PTT (Partial Thromboplastin Time)  
o INR (International Normalized Ratio)  
 Pregnancy test (if applicable)  
 
5.5.2  Electrocardiogram test (EKG)  
QT interval and QTc interval will be collected from each EKG, along with any abnormalities 
noted in the interpretation  
 
5.5.3  Transfusion Information  
Type of transfusion (e.g., packed red blood cells, fresh frozen plasma) and number of units will 
be collected  
 
5.5.4  Clinical Assessments  
 
The secondary objective of this study is to evaluate the  impact of NCG treatment on the 
functional status scale. During each admission, the functional  status scale will be evaluated 
prior to the start of study drug, as well as every day thereafter, until discharge or until episode 
treatment completion of the st udy drug.  
 
5.5.4.1 Pharmacokinetic Assessments (CNMC & CHOP)  
 
*** THIS PROTOCOL SECTION ONLY PERTAINS TO CHILDREN’S NATIONAL 
HOSPITAL AND CHILDREN’S HOSPITAL OF PHILADELPHIA (CHOP) ***  
 
Left over plasma or serum from any sample drawn for clinical laboratory  tests will be saved 
for pharmacokinetic (PK) analysis to be paired with study drug dosage and time of 
administration. The plasma  and/or serum samples will be stored frozen at -20˚C and batch -
shipped on dry -ice to Atlanbio Laboratory ( Rue Graham Bell, ZI d e Brais – BP 40309, 44605 
Saint -Nazaire, Cedex, France)  for determination of N -carbamylglutamate levels at the end of 
each patient episode. Since study participants experience a high number of blood draws  for 
clinical tests, no additional blood will be dra wn specifically for PK analysis. There will be no 
schedule of assessments for PK samples. Instead, study staff at CNMC and CHOP sites will 
be encouraged to collect the left over plasma or serum samples during each 
hyperammonemia episode. The exact time and  date of the blood draw is recorded (and will 
correspond to the medical record) for each sample. These samples will be stripped of 
hospital identifiers and will be labeled with the study number and episode number before 
being shipped to the reference labor atory.  
 
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 32 of 58 
 5.5.5  Efficacy Assessments  
For the primary outcome, we will evaluate the plasma ammonia trajectory during episodes in 
which patients receive NCG vs. PLBO. Secondary outcomes will consist of FSS, and length of 
hospitalizations.  
 
5.5.5.1 Functional Status  Scale  
The Functional Status Scale (FSS) will be used to assess changes in the subject’s global 
functioning in the hospital setting. The measure will be obtained at baseline (i.e., prior to 
administration of study drug or placebo at each episode) and then daily during 
hospitalization up to discharge or for 7 days whichever is shorter. The scale includes 6 
domains; mental status, sensory functioning, communication, motor functioning, feeding, 
and respiratory status. Each domain is rated on a 5 -point scale fr om 1 (normal) to 5 (severe 
dysfunction), thus the range of overall scores is 6 to 30 (Table 4). The measure was 
designed to be quantitative, rapid, reliable, minimally dependent on subjective assessments, 
applicable to as broad an age range as possible, an d pertinent to hospitalized patients in as 
many inpatient environments as possible22. All individuals collecting data will be trained in 
the measure and can include medical professionals such as a nurse, genetic counselor, or 
physician investigator at the site.   
 
 
Table 2. The Functional Status Scale (from Pollack et al., 2009)  
 
 
5.5.6  Safety Assessments  
Safety assessments will consist of serious adverse events, adverse events, EKG tests, and 
safety laboratory measurements in the NCG vs. the PLBO group.  
 

Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 33 of 58 
  
 Treatment Compliance  5.6
Treatment logs will capture the timing and dosage of each occurrence of study drug administration. 
All treatments will be administered in the hospital so non -compliance with the medication is not a 
concern.  
 
 
 Study Termination/Stopping Rules   5.7
The study PI and Coordinating Center will seek input from the DSMB regarding the need to stop the 
study if either of the following events occurs: (a) Life -threatening adverse event that is clearly 
associated with drug hypersensitivity and/or (b) Unexplained  serious illness or death of one of the 
participants.  
 
The NIH and local IRBs (at their local site) or the site PI has the authority to stop or suspend this trial 
at any time. The Medical Monitor, DSMB, or FDA may recommend suspending or stopping the trial 
after a thorough review, due to evidence related to sa fety or efficacy based on planned interim 
analyses (see Section 7 on Safety Monitoring and Section 8.3.1 on Interim Analysis).  
 
 
 Subject Discontinuation  5.8
A subject will be discontinued from the study if s/he:  
 Is determined not to have PA, MMA, CPSD, or OT CD (as defined in Section 5.1.1.1)  
 Voluntarily withdraws or is voluntarily withdrawn from the study by his/her parents  
 
The study drug will also be discontinued if a subject:  
 Experiences a serious adverse event, deemed by the Medical Monitor and site PI to  be 
related to or likely related to study drug administration.  
 Has received a hepatic transplantation  
 Relocates to a location,  not within the catchment area of one of the other participating 
institutions  
 
If a participant drops from the study before its co mpletion, a narrative description of the reason(s) for 
discontinuation will be recorded on the Study Closeout Form (see Manual of Procedures).  
 
 
 Blinding  5.9
This is a double -blind , placebo -controlled  trial performed in children’s hospitals across the country . 
Handling, storage, dispensing, and record keeping of all study medication will follow a Pharmacy 
Manual, which will be developed by the Central Research Pharmacy at Children’s National 
Hospital . The Pharmacy Manual will define the responsibilities and pr ocedures of the Central 
Research Pharmacy and of the Site Pharmacies both of which will be unblinded.  
 
5.9.1  Type of Blinding  
The participants, their families, caregivers, and all research personnel at the sites, as well as the 
study chair and co-chair,  will be blinded to the identity of the drug (NCG or PLBO). The 
appearance of active and placebo tablets is nearly identical.  
 
5.9.2  Maintenance of Blinding  
 NCG and PBLO will be sent to each site pharmacy by the Central Pharmacy (CNMC).  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 34 of 58 
  Assigned NCG/PLBO doses will be prepared individually for each subject by the Site 
Pharmacy.  
 Identically labeled NCG/PLBO doses prepared by the Site Pharmacy will be dispensed 
by blinded hospital staff based on a prescription  from the blinded study physician.  
 An additional  supp ly of NCG/PLBO will be provided as needed based on each site’s 
enrollment rate to provide the doses of study medication for all newly enrolled subjects 
as well as a small supply to meet emergency needs at each site.   
 The individual Site Pharmacy will prepa re, blind and dispense unit doses of study 
medication for each enrolled subject from the drug supply while the subject is 
hospitalized.  
 All unopened medications will be stored at controlled refrigerated temperature (2 -8° C; 
36-46° F), and opened medication s will be stored at controlled room temperature (15 -30° 
C; 59 -86° F)  in a secure area in the site’s research pharmacy to which access will be 
limited to the research pharmacist and designated assistants. To maintain blinding, only 
the site pharmacist and d esignated assistants will have access to the secured area.  
 
5.9.3  Breaking the Blinding  
Treatment assignment should not be unblinded unless the Medical Monitor assesses that 
knowledge of drug assignment is required in order to assess how to treat a safety conce rn 
within a patient. The site investigator should contact the Coordinating Center immediately if 
he/she believes that knowledge of the treatment assignment will affect their decision regarding 
treatment of a safety concern.  
 
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 35 of 58 
 6 STUDY TREATMENTS  
 
6.1 Study Intervention  
Carbaglu® 200 mg Dispersible Tablets (N -carbamylglutamate), scored in three places, allowing each 
tablet to be broken into four 50 mg pieces.  
 
The target dose is 150 mg/kg/d for patients ≤15kg or 3.3 g/m2/day for patients >15kg, divided into t wo 
equal doses 12 hours apart. Each dose will be rounded to the nearest 50mg using the dosing 
nomograms provided. The maximum variance from the calculated target daily dose and the actual 
daily dose will be 23.5% or less. Study drug will be prepared for ad ministration according to the 
package insert.  The suspension has a slightly acidic taste and a white, cloudy appearance. 
Participants will either receive PLBO or the study intervention, NCG (Carbaglu®) 150 mg/kg/day for 
patients ≤15kg or 3.3 g/m2/day for patients >15 kg.    
 
 
6.2 Control (Placebo) Intervention   
The placebo and NCG tablets, which are produced by the same manufacturer and include the same 
inactive components look and taste similar. When the two tablets are suspended in solution, there is 
a slight  difference in a hue that is only distinguishable when the two solutions are observed side by 
side.  
 
 
6.3 Dispensing of Study Medications  
 Handling, storage, dispensing, and record keeping of all study medication will follow a 
Pharmacy Manual, which will be de veloped by the Central Research Pharmacy (CRP) at 
the Children’s National Hospital . The CRP Pharmacy Manual will define the 
responsibilities and procedures of the CRP and of the site pharmacies both of which will 
be unblinded.  
 The CRP will receive study m edication (NCG) and matched placebo (PLBO) from 
Orphan Europe.  
 Once the CRP and the Coordinating Center at Children’s National Hospital determine a 
site pharmacy is appropriately certified and ready to receive the drug, the CRP will ship 
an initial quantit y of NCG and PLBO to the individual site research pharmacy.  
 All doses  of NCG/PLBO (as assigned) will be prepared, blinded, and dispensed in unit 
doses individually for each subject by each site pharmacy while the subject is 
hospitalized.  
 
 
6.4 Provisions for Access to Investigational Treatment after Study  
The results of the study will be shared with the patient, his/her family, and his/her treating physician. If 
the study reveals that NCG is effective, the treating physician will have the prerogative for trea ting the 
patient off -label with NCG, which is already approved for use in NAGS deficiency, until it is approved 
by the FDA for additional indications.  
 
6.5 Drug Packaging/Handling/Storage/Accountability  
 Oral NCG and matching PLBO will be supplied by Orphan Eu rope and distributed to 
each site by the CRP  
 The designated research pharmacist, investigator, or coordinator at each participating 
site will be required to acknowledge receipt of study drug shipments/doses and notify the 
CRP of any problems with shipments  or with the on -site supply of study medication.    
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 36 of 58 
  S/he will sign receipts for medication supplies, which will be kept in a secure area in the 
site’s research pharmacy to which access will be limited to the research pharmacist and 
their designated assistan ts. To maintain blinding, only the site pharmacist and 
designated assistants will have access to the secured area.  
 Unopened bottles of medications will be stored at controlled refrigerated temperatures 
(2-8° C; 36 -46° F).   
 Opened bottles of medications wil l be stored at controlled room temperature (15 -30° C; 
59-86° F) . The date of first opening a bottle will be recorded on the tablet container.  
 Drug accountability logs will be completed by the site pharmacists and the study 
coordinators.    
 The sites will update their monthly supplies logs and expiration dates and the information 
will be monitored by the central pharmacy.  
 Unopened bottles of medications will not be used after the expiration date stated on the 
tablet container. Opened containers of medicatio ns will not be used after 30 days of first 
opening.  
 All unused study medication will be returned by the site to the central pharmacy and be 
documented in the study database. After reconciliation, the drug will be destroyed or 
retained and used in animal re search.   
 At the conclusion of the study or as required for review, supplies of received, dispensed  
and returned medication will be reconciled to account for all distributed supplies of 
PLBO/NCG.  
 
 
6.6 Concomitant Therapy  
 
6.6.1  Therapies Prohibited Before/During the Trial  
All investigational drugs, biologics,  and therapies are prohibited following enrollment in this trial.  
 
This includes the use of alternative pathway medications, including sodium benzoate, and any 
medication with phenylacetate as an active metabolite (e.g., Buphenyl, Ammonul, Ravicti) in 
propionic acidemia, and methylmalonic acidemia ; these medications have not been approved 
for this indication and there is no evidence for their effectiveness in these conditions.  
 
No other changes in the sp ecial diet or medications are called for in this protocol.  
 
6.6.2  Therapies Allowed During the Trial  
Standard therapy, including but not limited to intravenous fluids, dextrose, intralipids, biotin, 
hydroxocobalamin, levocarnitine, metronidazole, and metabolic specialty formulas. 
Hemodialysis or hemofiltration may be administered as determined by the treating physician.  
 
In CPSD and OTCD, FDA approved alternative pathway medications (e.g., Na -benzoate, Na -
phenylacetate, Buphenyl, Ammonul, Ravicti) are allowed  and are indicated in these conditions.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 37 of 58 
 7 SAFETY MONITORING  
 
The study protocol will be submitted to the FDA under IND # 68,185 and will be reviewed by the study 
DSMB (Section 7.2) and the Medical Monitor (Section 7.3). Participant enrollment may only begin  after 
final IRB approval.  
 
7.1 Adverse Events (AEs)   
 
7.1.1  Definitions  
 
7.1.1.1 Adverse Event and Suspected Adverse Reaction  
As defined in title 21 of the Code of Federal Regulations Part 312, an adverse event (AE)  is 
“any untoward medical occurrence associated with the use of a drug, whether or not 
considered drug related”. All adverse events will be classified using version  4.0 of Common 
Terminology Criteria for Adverse Events (CTCAE), developed and maintained by CTEP at 
the National Cancer Institute ( http://evs.nci.nih.gov/ftp1/CTCAE/About.html).  
 
A suspected adverse reaction  is any adverse event for which there is a reasonable 
possibility that the drug (NCG) caused the adverse event. "Reasonable possibility" mean s 
that there is evidence, such as a temporal relationship, to suggest a causal relationship 
between administration of NCG and the adverse events. It is less certain about causality 
than adverse reaction . 
 
7.1.1.2 Serious Adverse Events  
Title 21 of the CFR also provides a definition for serious adverse events (SAEs), described 
as those events that result in death; or are life -threatening; or require prolonged inpatient 
hospitalization or prolongation of existing hospitalization, or  create persistent or signi ficant 
disability/incapacity, or a congenital anomaly/birth defects. However, application of this 
definition is difficult in subjects who, because of their underlying congenital disorder, present 
with a life-threatening  illness, requiring lengthy inpatient  hospitalization.  
 
Administration of NCG has not been described to result in serious adverse events (see side 
effects section 1.3.4), and using the standard definition of SAEs is likely to result in capture 
of events secondary to the underlying acute meta bolic disease, and which would not be 
helpful in the collection of data pertaining to NCG or its administration. Therefore, for this 
study, we modify the standard definition  and define serious adverse events  as those 
events that : 
 Result in death  
 Are life -threatening, that is, places the patient at immediate risk of death from the 
event as it occurred. Because acutely ill patients with PA or MMA are likely to 
experience life -threatening events as part of their underlying condition and meeting 
eligibility cri teria, this category will be restricted to events that arise as new events 
subsequent to administration of NCG, not having started prior to administration of 
NCG. Life -threatening events resulting from processes, which based on the opinion 
of the investiga tor likely began prior to administration of NCG  but had not been 
identified because the diagnostic investigation had not yet been performed, will not 
be considered serious adverse events.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 38 of 58 
  Require prolongation of existing hospitalization. This category will  be restricted to 
only complications that clearly extend the hospitalization that was anticipated at 
randomization to an episode.  
 
Serious Adverse Events in between episodes  
 Result in death  
 Are life –threatening  
 Require hospitalization (except for elective hospitalizations for e.g. elective 
procedures and hospitalizations for a hyperammonemic event which are episodes 
and not SAEs)  
 Note: if a hospitalization occurred without an episode -qualifying ammonia level, but 
later in the course of the hospitalization, the ammonia level rises to a qualifying 
episode, the participant will be randomized to treatment and the hospitalization will 
not be considered an SAE.  
 Cause prolongation of existing hospitalization  
 Cause persistent or significant disability/incapacity  
 Cause a congenital anomaly/birth defects   
 
 
7.1.1.3 Expected and Unexpected Adverse Events  
An unexpected adverse event or reaction is defined as any adverse experience, the 
specificity or severity of which is not consistent with the risks described in the protocol (see 
Section 1.3.4 on Safety and Side Effects of Carbaglu) or in the Carbaglu inve stigator’s 
brochure. Expected adverse events are those that are identified in the research protocol as 
having been previously associated with or having the potential to arise as a consequence of 
participation in the study or are part of the clinical spectr um of the underlying disorder. 
Common acute  and chronic complications of propionic and methylmalonic acidemia include:  
 Anorexia  
 Vomiting  
 Lethargy  
 Stupor  
 Coma  
 Seizures  
 Ketosis  
 Acidosis  
 Hyperventilation  
 Hyperglycemia  
 Hypoglycemia  
 Hypothermia  
 Neutropenia; bon e marrow suppression  
 Electrolytes abnormalities  
 Amino acid abnormalities  
 Pancreatitis (PA)  
 Renal dysfunction (MMA)  
 Cardiomyopathy (PA)  
 
 
7.1.1.4 Relationship to Intervention Assessment  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 39 of 58 
 Relationship of NCG to the adverse event or suspected adverse reaction is defined as 
follows:  
 Unrelated:   
Adverse event is clearly due to extraneous causes (e.g., underlying disease)  
 
 Unlikely related (must have 2 of the below):  
Does not have temporal relationship to NCG administration  
Could readily have occurred due to subject's clinical state  
Could have been due to environment or other interventions  
Does not follow known pattern of response to NCG  
Does not reappear or worsen with reintroduction of NCG  
 
 Possibly related (must have 2 of below):  
NCG administration and the occurrence of the AE are reasonably related in time  
Could not readily have occurred due to subject's clinical state  
Could not readily be due to environment or other interventions  
Follows a known pattern of response to NCG  
 
 Probably related (must have 3 of the below):  
NCG administration and the occurrence of the AE are reasonably related in time  
Could not readily have occurred due to subject's clinical state  
Could not readily be due to environment or other interventions  
Follows a known pattern of  response to NCG  
 
 Definitely related (must have all 4 of the below ):  
NCG administration and the occurrence of the AE are reasonably related in time  
Could not readily have occurred due to subject's clinical state  
Could not readily be due to environment or  other interventions  
Follows a known pattern of response to NCG  
 
7.1.2  Collection and Reporting of Adverse Events  
The site study coordinator is responsible for collecting and recording all clinical and laboratory 
data. Adverse events will be collected on subject s on each day of admission, as well as by 
phone or e -mail communication with parents when the study coordinator contacts subjects or 
their families to collect any adverse events that occurred in the 72 hours following episode 
treatment completion following  each admission. The reporting period for new AEs is the period 
from the start of study drug administration until the patient completes their participation in the 
study (i.e., until the end of the study period or until discontinuation if early withdrawal o ccurs) . 
Follow -up reports on AEs should continue up to 30 days after the administration of study 
treatment if the AE did not resolve.  
 
For each AE, the site investigator will assess severity, and whether the event meets the 
definition of a serious adverse event (see Section 7.1.1) and will report whether study treatment 
was interrupted or stopped, as well as the outcome of the AE. If the event is an SAE, both the 
site PI and the Medical Monitor will assess the relationship to study treatment. As described i n 
5.7.3, treatment assignment should not be unblinded unless the Medical Monitor assesses that 
knowledge of drug assignment is required in order to assess how to treat a safety concern 
within a patient.  
 
If a non -serious adverse event is unresolved at the time of discharge from the study, the site PI 
will make a clinical assessment as to whether continued follow -up of the AE is warranted. The 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 40 of 58 
 site PI may request input from the Medical Monitor. Resolution is defined as the return to 
baseline status or stabil ization of the condition with the expectation that it will remain chronic.  
 
The CNMC -CC will prepare aggregate reports of all adverse events (serious/not serious and 
expected, unexpected) for the DSMB as required and for the FDA on an annual basis. Local site 
investigators are also required to fulfill all reporting requirements to their IRB and to the CNMC -
CC. 
 
7.1.2.1 Reporting of Serious Adverse Events  
Serious adverse events (SAEs) must be reported by each site PI to the CNMC -CC within  
24 hours of learning of the event. The CNMC -CC has a  joint phone & email tree for 
reporting SAEs to the CNMC -CC at any time. Those involved in the phone & email tree are 
aware that they may expect to receive a phone call or email at any time for an SAE. T he site 
reporting the SAE must attempt to call or email first the CNMC -CC Principal Investigator 
(PI), followed by the Project Manager (PM), and then the Data Manager (DM) until someone 
has been reached in real time. It will be the responsibility of the CN MC-CC PI, PM, and DM 
to have a backup point of contact for instances of sick leave or vacation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Medical Monitor (or their delegate) will then be contacted by the CNMC -CC and be 
informed of the details of the SAE. The CNMC -CC will immediately report unexpected SAEs 
to the CNMC IRB according to local guidelines.  
 
Sites are required to submit follow -up reports to the initial report as promptly as is feasible. 
The CNMC -CC will submit a report of the SAE to the FDA within 1 5 calendar days of the 
event  if the event meets the reporting requirement of a serious and unexpected suspected CNMC -CC Principal Investigator  
Nicholas Ah Mew, MD  
nahmew@cnmc.org  
202-577-9971  
202-476-5863  
CNMC -CC Project Manager  
Katie Rice, MPH, CCRP  
krice3@cnmc.org  
202-621-0062  
CNMC -CC Data Manager  
Sneha Saraf, MS  
ssaraf@cnmc.org  
315-751-7760  
202-476-2353  
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 41 of 58 
 adverse reaction ( SUSAR) . In those cases,  the CNMC -CC will also report the event to the 
DSMB. In all other cases, the CNMC -CC will submit the re port as part of periodic reporting 
to the DSMB and FDA.  
 
The Medical Monitor will review causality (unrelated, not likely related, possibly related, 
probably related, definitely related) of the serious adverse event. The Medical Monitor may 
request further information if necessary and possibly request changes to  the protocol or 
consent form as a consequence of the adverse event.  
 
Additionally, site investigators will be responsible for reporting SAEs to their IRB within the 
time mandated by the site IRB. The CNMC -CC will inform all sites of any safety updates or  
changes, and the site investigators will be responsible for notifying their local IRB of these 
modifications. The CNMC -CC will ensure that all SAEs and any safety updates or changes 
are reported to the site’s IRB by collecting a copy of all IRB -related co rrespondence and 
reviewing regulatory submissions during monitoring visits.  
 
7.2 Data and Safety Monitoring Board (DSMB)  
A DSMB will be assembled by the investigators. Typically, the Board members represent the 
following specialties, all of whom will have no formal involvement with the participants or the 
investigators: a medical doctor with experience in inherited metabolic disorders, a neonatologist, a 
biostatistician, and the clinical trial coordinator. This Board is responsible for safety and accuracy 
moni toring of the data entered by the investigators. The DSMB will regularly evaluate trial 
performance, monitor interim data for safety and effectiveness of study regimens, review any protocol 
modifications, and advise the investigators regarding early termin ation or continuation of a study 
based on the interim monitoring or scientific findings. The DSMB will receive and respond to reports 
of any serious adverse events (SAEs) and will be immediately notified of fatal or life -threatening 
events. Based on the re view of safety, efficacy, and performance data, the DSMB will make 
recommendations regarding the conduct  of the study. It is expected that the DSMB will meet at least 
biannually in Washington, D.C., with conference calls as necessary.  
 
7.3 Medical Monitor  
A Medical Monitor has been identified by the investigators. The Medical Monitor is responsible for 
being available by pager to monitor study safety issues  and must identify an appropriate delegate to 
provide coverage whenever he is not available. The Medical Monitor (or designee) will be contacted 
whenever a critical situation with a patient arises and a decision about unblinding the  treatment 
assignment must be made (i.e., in the event that unblinding the treatment assignment would affect 
subsequent managemen t of the patient). The Medical Monitor may be unblinded whenever he deems 
it necessary. The Medical Monitor will also conduct an independent blinded review of all Serious 
Adverse Events (SAEs) and will contribute to the preparation of all SAE reports. The Medical Monitor 
will communicate any identified safety concerns to the study PI and Coordinating Center. The Medical 
Monitor may consult with the DSMB.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 42 of 58 
 8 STATISTICAL ANALYSIS  
 
8.1 Study Aims  
 
8.1.1  Primary Aim  
The primary aim is to evaluate the impact of NCG treatment during hyperammonemic events on 
the resolution of ammonia levels, among patients diagnosed with severe PA or MMA and partial 
CPSD or OTCD.   
 
8.1.2  Secondary Aim  
Secondary analyses will also evaluate the  safety of NCG. Safety is a secondary aim because 
there is already evidence that NCG, which is approved by the FDA for use in the treatment of 
NAGS, poses no serious risks to patient safety. Therefore, the focus of this research is less on 
safety than on i ts effectiveness in treating PA and MMA, which share the common risks 
associated with hyperammonemia with NAGS. The analysis of safety will focus on three 
outcomes; these include the level of selected laboratory markers related especially to organ 
health, the frequency of reported symptoms, and the frequency of reported adverse events by 
seriousness. The analysis of laboratory markers will compare the time specific and time 
averaged mean levels of each marker by study group. In addition, we will compare the  
frequency of symptoms and adverse events, relying mainly on tabulations by a study  group of 
reports by organ system paying most attention to the magnitude of the difference between 
groups and consistency of the evidence than on formal hypothesis testing.  
 
 
8.2 Factors for Stratification  
Because clinical management practices and referral patterns may vary from site to site, stratification 
during randomization by the site will ensure that episodes will be balanced across study groups within 
each site.   
 
 
8.3 Stati stical Considerations  
Experience with models evaluating the overall  change in ammonia level during episodes following 
randomization (not divided by treatment group) has demonstrated that the shape of the ammonia 
curve is more variable and more complex than  envisioned during study design. This circumstance 
has made it difficult to see how to generate a stable model to properly reflect and compare the slope 
of ammonia decline by treatment group as the primary outcome.  
Challenges included the following:  
1. The need to introduce curvilinearity in order to model change appropriately; and  
2. The need to also rely on piecewise regression models to adequately model bends or  
points of inflection in the curve.  
 
The latter has proven especially difficult to manage because methods vary in their recommendation 
regarding the number (1 vs 2) and position (time point of each bend) to define piecewise regression 
segments. This variability would lead to the need to creat e a number of alternative models that would  
affect the interpretation  of results with no clear way to prioritize the choice of the final model.  
 
This situation prompted us to choose an alternative composite outcome and modeling strategy based 
on time to r each an ammonia level of 50 mcmol/L or time to discharge whichever occurs first. This 
approach avoids the complexity of modeling the correct shape of the ammonia decline curve but 
provides a rigorous, well -defined, and clinically -relevant outcome for compa rison of treatment effects. 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 43 of 58 
 The choice of 50 mcmol/L as the target for ammonia decline is based on the extensive experience of 
metabolic physicians that a patient reaching this level of ammonia is no longer at risk of acute 
hyperammonemic injury and would be a candidate for discharge in the absence of other 
complications, which are not hypothesized to be affected by treatment with NCG.   
 
We propose to use Cox Proportional Hazard modeling to implement the primary analysis to compare 
the average differences in time to reach the composite outcome and allow us to control for 
differences in severity (ammonia level and or FSS) at episode baseline. This method will also allow 
us to take account of and adjust statistical testing for the correlation between results of participants 
who contributed more than one event to the analysis. The comparison of slopes of the ammonia 
decline curves by treatment group will shift to secondary analysis, which will allow us to focus on 
consistency of results rather than choosing the  precise model for significance testing for the purpose 
of rejecting the null hypothesis of no treatment effect.  
 
Study analyses will be based on an intention -to-treat paradigm. In analyzing the primary outcome, we 
will evaluate the difference over time i n the probability of reaching an ammonia level of 50 mcmol/L or 
hospital discharge. For this purpose,  we will use a z -test to assess the evidence  that the hazard 
(event) ratio (HR) differs from 1 ( no effect ) to test for a difference in the probability of t he composite 
outcome over time by the group. We will account for the correlation between repeat episodes per 
participant by treating participant episodes with the same ID as a cluster, which will adjust standard 
error estimates for the intraclass correlati on between episodes in the same cluster. The primary 
analysis will be implemented using the sts cox procedure in Stata 14 ( StataCorp. Stata Statistical 
Software: Release 14 , College Station, TX: StataCorp LP, 2015 ).  
 
Secondary efficacy outcomes are based on groupwise  comparisons of the trajectory (slope) of 
ammonia decline, FSS, and time -to-hospital -discharge during hyperammonemia episodes. For 
analysis of the ammonia decline trajectory and FSS analysis,  we will implement longitudinal linear 
hierarchical m odels. The models will enable us to estimate and compare the slope(s) based on 
ammonia change trajectory over time, as well as the time, averaged FSS across all episodes treated 
with NCG vs. PLBO. For time to discharge comparisons, we will rely on the same  Cox Regression 
Analysis described for the primary outcome except the outcome event will be limited to time to 
discharge. As in the primary analysis, we will adjust model error for the clustering of observations by 
patient and control for severity based on  ammonia level or FSS at admission to each episode. To 
assess NCG safety we will compare the levels/frequency of laboratory test results, reported 
symptoms, and adverse events. Secondary analyses will control for indicators of episode severity, 
e.g. peak a mmonia.  
  
8.3.1  Interim Analysis  
In addition to the proposed final analysis, we will conduct an interim analysis using the same 
methodology described above when at least 50% (70 episodes) or when at least 60 episodes 
have occurred after the study midpoint based on the projected 4 hyperammonemic events per 
participant have been completed  (participant discharged). Allowing for one interim look for both 
efficacy and futility when half the information becomes available, using an O’Brien -Fleming 
stopping rule and a L an-DeMets approach to the use function of the p -value.  If conducted 
exactly at the 50% outcome, the boundary for rejecting the null hypothesis and concluding that 
Carbaglu is either efficacious or worse that placebo is a z -score of +/ -2.9626, corresponding  to 
a p-value <0.0031 at the interim look. The boundary for deciding futility, i.e., that Carbaglu is not 
expected to be significantly different than placebo is +/ -0.3557, corresponding to a p -value of 
>0.72 at the interim look. With these boundaries, the decision rules at the conclusion of the 
study will be +/ -1.9686 or more extreme to conclude that Carbaglu is either efficacious or worse 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 44 of 58 
 than placebo, corresponding to a p -value of <0.049. These values were calculated using East 
5.3 (Cytel, Inc.).  
 
A repor t of the interim analyses will be provided to the DSMB, which will review and discuss the 
results considering all evidence available, including magnitude of difference between groups 
and p -value, as well as results on secondary outcomes and safety to consi der whether the 
results warrant stopping the trial either from persuasive evidence of benefit or harm.  
 
8.4 Rationale for Sample Size and Statistical Power  
All sample size and power estimates are based on 2 -tailed testing, which assumes a type 1 error of 
5% and achieving 80% power to detect an HR difference by treatment group and that there is no 
censoring  as each episode will contribute information to one of  the composite outcomes. We used the 
Cox Regression procedure in PASS (Hintze, J. PASS 11. NCSS, LLC. Kaysville, Utah, USA. 
www.ncss.com , 2011) to evaluate the composite time to event outcome of the  earlier of the time t o 
reach an ammonia level of 50 mcmol/L or time to discharge within hyperammonemic episodes (the 
unit of randomization and analysis). We evaluated HR estimates above 1, reflecting that the NCG 
group achieved the higher probability of achieving the composite  event. Based on these 
considerations, a total sample size of N=146 episodes can detect an HR of 1.6, one of N=114  can 
detect an HR of 1.7, one of N=93  can detect an HR of 1.8 and one of N=78  can detect an HR of 1.9. 
These sample size estimates account for  an inflated R -square as large as 0.05 between the time to 
event outcome and covariates reflecting baseline severity at the start of an episode. We used the 
inflated R -square to account for the modest effect of clustering of episodes within a person . 
There fore, we consider the originally -targeted sample size of 144 episodes to be more than sufficient 
to meet the aims of the study. Based on our re -analysis of the time -to-event outcome, an HR of 1.7 is 
realistic and a sample size of 114 episodes is sufficient  to detect that effect. Therefore, the target 
sample size will be 114 episodes.  
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 45 of 58 
 9 REGULATORY COMPLIANCE AND SAFETY MONITORING  
 
9.1 Regulatory Compliance  
This clinical trial will be conducted in accordance with the protocol, the ICH Harmonised Tripartite 
Guideline “Note for Guidance on Good Clinical Practice,” and the applicable local regulatory 
requirements.  
 
9.2 Statement of Compliance  
The CNMC IRB and all participating site IRBs comply with Good Clinical Practices as defined by the 
U.S. Food and Drug Admini stration (FDA) regulations and the International Conference on 
Harmonization (ICH) guidelines.  
 
Investigator Assurances  
 For quality assurance reasons, the Coordinating Center reserves the right to perform site -
monitoring visits.  
 Monitoring shall ensure that the study is planned, conducted, evaluated, and reported 
according to  this protocol and the applicable SOPs of the Coordinating Center, the ethical 
principles that have their origin in the Declaration of Helsinki (1996), the re quirements of 
the ICH Harmonised Tripartite Guidelines.  
 Monitoring shall also ensure that the documentation of the study is available, complete, 
organized, and valid.  
 The investigator agrees to give the study monitor access to all relevant documents, 
including source documents, for review. The same applies in the case  of an inspection of 
federal authorities or the relevant IRB.  
 
9.3 Informed Consent  
 It is the responsibility of the investigator to ensure that no subject is enrolled in any study -
related examinat ion or activity before written informed consent has been obtained.  
 Written informed consent will be obtained from subjects or their legal representative(s) in 
compliance with 21 CFR Part 50 and the ethical principles that have their origin in the 
Declarat ion of Helsinki.  
 For underage subjects, written informed consent will be obtained from the subject’s legal 
representative(s) (e.g., his/her parent(s) or legal guardian(s)) in compliance with 21 CFR 
Part 50 and the ethical principles that have their origin in the Declaration of Helsinki.  
 If the subject is younger than the age of consent  but old enough to provide assent, it is the 
investigator’s responsibility to ensure that the site’s assent procedures are followed and 
that there is documentation of the fac t that the assent procedures were followed. The 
subject and the subject’s legal representative(s) will be informed that they are completely 
free to refuse to enter the study or to withdraw from it at any time and that this will not 
affect their overall car e at the institution.  
 If the subject’s mental age or psychological state is such that they cannot assent or if there 
is potential medical benefit to the subject by participating in the study an assent waiver 
must be signed by a parent or legal representati ve. 
 Subjects, whose legal representative(s) refuse to give written informed consent or 
withdraw their informed consent, later on,  must not be included in the trial or must be 
excluded from further participation, respectively.  
 Before personally dating and signing the informed consent form, the subject’s legal 
representative(s) will be informed in detail by the investigator about all pertinent aspects of 
the trial according to 21 CFR Part 50 and ICH GCP.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 46 of 58 
  The subject’s legal representative(s) should be given  sufficient time to request further 
details about the trial before signing the informed consent form, in accordance with the 
ICH GCP Guidelines (1997). Under certain circumstances, when a patient cannot provide 
informed consent and is not accompanied by pa rents/guardians,  the investigator will 
speak with the parent/guardian by phone, and provide them with a copy of the consent 
form (e.g., by fax, e -mail). When the parent/guardian receives the consent form, it will be 
immediately signed and sent/faxed back to the investigator.  
 The receipt of the informed consent from the legal representative(s) must be documented 
on the appropriate page of the subject’s CRF and in the source documents.  
 One copy of the consent form signed and dated by the subject’s legal rep resentative(s) 
and by the physician who informed the legal representative(s) will be kept at the study site; 
a second copy will be provided to the subject’s legal representative(s).  
 
9.4 Records Retention and Requirements  
 The investigators and the sponsor(s) must archive all essential records and documents 
including but not limited to CRF, informed consent, and identification codes for subjects 
and other original records.  
 These documents of the study will be retained at le ast 3 years after study close and data 
lock. 
 The site investigators will be informed by the Coordinating Center (CNMC -CC) when the 
documents need not be retained any longer.  
 
9.5 Financial Disclosure  
Financial disclosure information will be collected per Part 54 of Title 21 of the CFR and ICH E6. In 
addition, the site investigators must provide to the study PI a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 1 year 
following completion  of the study.  
 
9.6 Inclusion of Minorities and Children  
The disorders to be investigated affect both genders and all different ethnic groups and we, therefore,  
expect to have proportional representation among the participants of the trials. These are rare 
disorders, and we will attempt to recruit all presenting potentially eligible patients. Participants of this 
study will include neonates, infants, children, adolescents, and adults. There is no upper age limit.  
 
9.7 Confidentiality  
By conducting this study, the i nvestigator pledges that he/she will keep all information pertaining to 
the study strictly confidential, including data generated from this study, except as exempted for 
regulatory purposes. Blood samples  and neuropsychological testing will be collected an d diagnostic 
records will be reviewed. Data recorded will include demographics, clinical summary, diagnostic tests 
and study results. All research data will be accessible only to the research team and as required by law.  
9.7.1  Protection Against Risk  
 The NCG drug and placebo will be handled by the respective site investigational drug 
pharmacy and will be dispensed by that pharmacy.  
 The participants and their families will be provided psychological and emotional support 
to deal with the results of the developmental testing.  
 Venipuncture:  The vein in which the needle has been inserted to draw blood may 
become sore and red. A temporary bruise may develop, and rarely fainting may occur.  
 Confidentiality is protected to the full extent required by law and  applicable local, State 
and Federal regulations and guidance including HIPAA.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 47 of 58 
  All medical records, including case report forms, will be kept in locked files accessible 
only to the health professionals involved in the clinical research or responsible for the 
participant’s care, governmental agencies (e.g., FDA, NIH), and local convening 
authorities (e.g., IRB) for the purpose of audit regarding scientific validity and/or aspects 
pertaining to the ethical conduct of human clinical investigation. Identifier data are not 
released without the parent/participant’s knowledge and consent. Electronic databases 
are user ID/password protected.  
 The results of the study will be shared with the participant of the study as soon as they 
become available.  
 
9.7.2  Health Insuran ce Portability and Accountability Act (HIPAA)  
The Standards for Privacy of Individually Identifiable Health Information (“Privacy Rule”) 
establishes a set of national standards for the protection of certain health information. The U.S. 
Department of Health  and Human Services (HHS) issued the Privacy Rule to implement the 
requirement of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
 
The Privacy Rule standards address the use and disclosure of individuals’ health information —
called protected health information (PHI) by organizations subject to the Privacy Rule — called 
“covered entities”, as well as standards for individuals' privacy rights to understand and control 
how their health information is used.      
 
Under HIPAA, Protected h ealth information encompasses 18 identifiers, which must be treated 
with special care, including information on a patient's medical chart or a patient's test results, 
contact information, as well as an individual's billing information for medical services rendered. 
PHI also includes identifiable health information about subjects of clinical research gathered by 
a researcher who is a covered health care provider. This study does not collect any PHI except 
dates, and other are considered a limited data set.  
 
For this portion of the study, which involves a minimal data set of PHI for recruitment purposes, 
only the mini mum necessary information required to accomplish the research objectives will be 
extracted from the electronic medical record and recorded in the research database. Allowing 
the study team to use the electronic medical record to identify and capture inform ation about all 
potentially eligible subjects is necessary to meet the research objectives.  
 
9.8 Regulatory Files  
Prior to beginning the study, the study Principal Investigator and Site Investigators will be asked to 
comply with ICH E6 8.2 and Title 21 of the CFR by providing the following essential documents, 
including but not limited to:  
 An original investigator -signed Investigator Agreement page of the protocol.  
 An IRB -approved informed consent, samples of site advertisements for recruitment for 
this study, and any other written information regarding this study that is to be provided to 
the subject or legal guardians.  
 IRB approval of the protocol and amendments.  
 Form FDA 1572, fully executed, and all updates on a new fully executed form FDA 1572  
 Curriculum vi tae (CV) for the site Principal Investigator and each Sub -Investigator listed 
on Form FDA 1572. Current licensure must be noted on the CV. They will be signed and 
dated by the site Principal Investigators and Sub -Investigators at study start up, 
indicating  that they are accurate and current.  
 Financial disclosure information to allow the sponsor to submit complete and accurate 
certification or disclosure statements required under Part 54 of Title 21 of the CFR and 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 48 of 58 
 ICH E6. In addition, the Investigators must provide to the study PI a commitment to 
promptly update this information if any relevant changes occur during the course of the 
investigation and for 1 year following the completion of the study.  
 Laboratory certifications and normal ranges for any test or assay being performed.  
 
9.9 Source Data Verification Monitoring  
 The study PI will authorize the Coordinating Center (CNMC -CC) to monitor the study 
according to the relevant standard operating procedures (SOPs) and GCP guidelines as 
frequently as deemed necessa ry by the CNMC -CC to verify that data entries into the 
CRF are correct and that the study is conducted in accordance with this protocol. The 
first monitoring visit will take place approximately 12 months after the Site Initiation Visit.  
 During each monitor ing visit, the monitor will check the entries made in the CRFs. The 
monitor will compare these entries with the source data, e.g., the subject’s medical 
records or laboratory results (source data verification). The case number, informed 
consent, demographi c data, inclusion/exclusion criteria, concomitant diseases, 
concomitant treatment, and all AEs will be verified.  
 The monitor will check all data for plausibility and completeness in collaboration with the 
site investigator. At the same time, a data check for medical plausibility and conformity 
with ICH GCP will be performed.  
 
9.10 Modification of the Protocol  
Protocol modifications that affect the safety of the subjects or that alter the scope of the investigation, 
the scientific quality of the study, the exper imental design, dosages, assessment variable(s), the 
number of subjects treated, or the subject selection criteria may be proposed by the study Principal 
Investigator and the Medical Monitor. Any change to the protocol can be made only in the form of a 
written amendment to this study protocol. Such amendments must be approved by the DSMB and the 
institutional IRB of the study PI and the CNMC -CC first. Once approved, these amendments will be 
circulated to the sites for their IRB approval prior to implementat ion at each site.  The IRB at each site 
will determine if the changes are such to warrant that the informed consent form must be revised and 
re-signed by the legal representatives of all subjects enrolled in the trial, or only applied to new 
subjects in th e study.  
 
9.11 Protocol Deviations and Violations  
Protocol deviations or violations are any non -adherences to the procedures outlined in this document. 
After a subject has been enrolled, it is the investigator’s responsibility to make any reasonable effort 
to avoid and, if necessary, correct protocol deviations or violations  
 
Protocol Deviation  
A protocol deviation is any change, divergence, or departure from the IRB -approved protocol, 
which does not affect the subject's rights, safety or well -being, or the comp leteness, accuracy,  
and reliability of primary study data.  
 
Protocol Violation  
A protocol violation is any change, divergence, or departure from the IRB -approved protocol that 
may affect the subject's rights, safety, or well -being and/or the completeness, accuracy,  and 
reliability of primary study data.  
 
If any of the following five criteria are met, a protocol violation has occurred (examples 
provided):  
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 49 of 58 
 1. The deviation has harmed or posed a significant or substantive risk of harm to the 
research subject.  
• A research subject received the wrong treatment or incorrect dose or expired drug  
• A research subject met withdrawal criteria during the study but was not withdrawn  
• A research subject received an excluded concomitant medication  
2. The deviation compromises  the scientific integrity of the data collected for the 
study.  
• A research subject was enrolled but does not meet the protocol's eligibility criteria  
• Changing the protocol without prior IRB approval  
3. The deviation is a breach of human subject protection regulations, policies, or 
procedures on the part of the investigator(s).  
• Failure to obtain informed consent prior to initiation of study -related procedures  
• Falsifying research or medical records  
• Performing tests or procedures beyond the individual's professional scope or 
privilege status (credentialing)  
4. The deviation involves a serious or continuing noncompliance with federal, state, 
local, or institutional human subject protection regulations, policies, or 
procedures.  
• Working under an expired profe ssional license or certification  
• Failure to follow federal and/or local regulations, and intramural research or 
Coordinating Center policies  
• Repeated minor deviations  
5. The deviation is inconsistent with the NIH Human Research Protection Program’s 
resear ch, medical, and ethical principles.  
• A breach of confidentiality.  
• Inadequate or improper informed consent procedure  
 
All protocol violations will be reported by the site to the CNMC -CC immediately upon discovery . The 
CNMC -CC will report to the study PI  any violations reported by sites or discovered through 
monitoring. All protocol violations will be listed and the admissibility of the subjects’ data will be 
reviewed and assessed by the CNMC -CC. In case any emergency or AE occurs that requires a 
protocol  deviation in the particular case, the investigator should contact the Medical Monitor and 
DSMB as soon as possible to enable a decision on whether the subject’s participation in the study 
may be continued.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 50 of 58 
 10 DATA MANAGEMENT AND PROCEDURES  
 
All study dat a will be collected via systems created at the CNMC Coordinating Center (CNMC -CC) and 
will comply with all applicable guidelines regarding patient confidentiality and data integrity .   
 
10.1 Data Collection  
Data can be captured either on paper source documenta tion and then entered into the Research 
Electronic Data CAPture (REDCap) system or  entered directly (https://redcap.vanderbilt.edu). The 
web-based transmission of data is encrypted and enclosed within a firewall . 
Copies of all source records (original consent documents, contact notes, laboratory evaluation, and 
other diagnostic reports) must be kept in the participants’ medical record or in a separate research 
chart as allowable by institutional guidelines. At a minimum, the participants’ medical record  and 
study chart must contain a copy of the informed consent. The participant’s medical record must 
contain the source documents.  
 
10.2 Data Processing  
Data will be entered into REDCap by site study staff and using data validity and cleaning applications 
within REDCap, all data will be checked against data specifications. Data exceptions (i.e., invalid 
values, outliers, etc.) or missing data are flagged a nd described to give the site coordinator an 
opportunity to review and make corrections directly in the database. All changes to the database will 
be logged in the REDCap data audit trail. Nevertheless, an eCRF containing data exceptions can be 
submitted  and is logged. Data exceptions, detected at multiple check levels, are queried  and 
followed. The Coordinating Center will also perform regular data queries.    
 
10.3 Design and Development of REDCap for Study Data Management  
We will collect and manage study data using the Research Electronic Data CAPture System 
(REDCap ) which has been used to successfully support more than  700  single and multi -centered 
clinical research studies at CNMC and The George Washington University as part of the collaboration 
between the se two institutions for the Clinical and Translational Research Institute at Children's 
National (CTSI -CN). REDCap contains tools that are designed to significantly enhance study 
management and improve the completeness, quality, security, and integrity of research data. The 
system provides support for all facets of an investigation including protocol oversight, screening,  and 
enrollment of volunteers, a collection  of protocol -driven data, as well as reporting and analysis of 
interim and final results. REDCa p also assists with monitoring patient safety and data quality. At 
enrollment, REDCap supports the random allocation of participants to study groups. In addition to the 
study data itself, the database houses information about each protocol including inform ation 
describing each item of data to be collected, targeted enrollment quotas, eligibility criteria, as well as 
the detailed schedule of visits with information to be collected at each visit (event -time matrix). This 
enables the system to help with study management and to help improve study quality. The system 
provides for Web -based data collection from professionally designed forms that can be accessed for 
online entry directly into the database. Using the Data Access Groups, REDCap also confines each 
site to view and edit only their own participant dataset. At entry, data checks are performed and data 
exceptions are logged and flagged for correction. Corrections are implemented based on data edits 
applied to online forms by approved personnel. All changes  are logged and subjected to the same 
validity and consistency checking of the original data and are applied directly to stored data.  
10.3.1  REDCap Time Event Matrix  
A key feature of REDCap are the event grids, which define and help to manage the study 
protocol, it is used as the fundamental view for both scheduling and management of protocol 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 51 of 58 
 events, including access to eCRFs. It provides per protocol, a complete and up -to-date picture 
of each participant’s status regarding expected and completed events by the target date.  
 
10.3.2  REDCap Protocol Management  
In terms of protocol management, the event grid also lists and tracks each of the data capture 
events that must take place to implement the research protocol and it provides monitoring to 
help assure that each is comp leted accurately (see Section 10.6) and that the requisite data 
reside in the database within the designated timeframe.  During the encounter,  it serves as a list 
to ensure that events that need to occur are completed according to protocol. It also provide s a 
“just in time” link to the eCRF used to record, view, and or edit the data.  Symbols are used to 
show the status of each event at each time point in the event grid. Initially, the symbol for each 
form will be red if the form has not been completed, yel low if the form has been completed but 
data have not been verified, and green when the form has been completed.   Visit window data 
will be used to identify any data collected outside of the allowable timeframes; these will be 
noted as protocol violations.     
 
10.3.3  REDCap Facilitated Screening Features  
REDCap will track study screenees  from the point of contact through enrollment . During the 
screening , REDCap will assign each screenee  a unique numeric study Screening ID, which is 
distinct from any personal ident ifiers.  The screening identifier will be selected from a range 
dedicated to each site. Screenees  are classified as “pending eligibility” while they are being 
evaluated  per eligibility criteria. Subsequently, they are labeled  as “eligible” or “ineligible”,  noting 
the reasons for ineligibility. Those meeting eligibility criteria are classified as “pending 
enrollment ” while they are being processed and later as “enrolled” or “refused” noting the 
reasons for their refusal once they have made their decisions. A t enrollment , each participant is 
randomly assigned to a study group and receives a Participant ID (PID), which is separate from 
the Screening ID. In addition to changes in the subject's recruitment status, the time of such 
changes is also recorded.  
 
10.3.4  REDCa p Randomization  
At each episode, online checks ensure all episode eligibility criteria are met, and if so, access is 
provided to the REDCap randomization button. When pressed,  the button implements an online  
program that accesses a pre -generated, encrypt ed, randomization schedule created by the 
CNMC Division of Biostatistics and Study Methodology to make the appropriate treatment  
assignment for that subject. This procedure will provide a balanced  allocation of assignments to 
each treatment arm over the ep isodes. Once an assignment is made, to maintain the blind the 
person enrolling the subject will be notified simply that the site pharmacy is preparing the 
assigned medication. These procedures will ensure tamper -proof, blinded randomization as well 
as over all balance in assignment to treatment groups. The Site Pharmacy will simultaneously 
receive online or fax notification of the assignment and will be requested to prepare the 
appropriate dosing kit for pick -up or delivery to the floor (depending on site lo gistics).  
 
10.4 Recruitment and Retention Monitoring  
REDCap reports will monitor recruitment overall and by the site. It will warn of recruitment problems 
by plotting actual vs. expected screens, recruits,  and enrollees. Should problems arise, REDCap can 
help diagnose the source of such problems, and identify possible remedies. It is also possible to 
compare the demographics of all those eligible  to all enrollees. These monitoring reports will be 
forwarded on a monthly basis to study leadership  and will be discussed at the weekly calls. Retention 
rates at each site will be evaluated on a monthly basis using REDCap reporting modules. Should a 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 52 of 58 
 site show an unexpectedly high loss to follow -up, causes of the problem will be reviewed, and 
possible changes to retention strategies will be evaluated.  
 
10.5 Site Data and Study Responsibilities  
Each site will:  
 Submit protocol and any protocol amendments or modifications to site IRBs for approval  
 Maintain  regular communications with the Coordinating Center regarding IRB protocol 
approvals  
 AEs or other study related issues  
 Attend regular conference calls to discuss milestones and administrative issues  
 Maintain study charts  
 Recruit, consent and enroll study participants  
 Conduct all study visits in accordance with the protocol and the Manual of Operating 
Procedures  
 Receive, log and account for all study drug from the central pharmacy, and will dispense 
drug to the study participants and will return unused or e xpired drug to the central pharmacy  
 Enter and verify all study data  
 
10.6 CNMC Coordinating Center Responsibilities  
In order to ensure that data are of the highest quality, special attention will be paid to project 
monitoring. Site performance monitoring will b e done by the Project Manager. Monitoring of 
milestones and data quality will be done both in -house at the CNMC -CC and during on -site 
monitoring.  
 
The internal component will consist of the CNMC -CC data manager performing a clinical review of the 
eCRFs. Th is process will supplement the range checks performed at the time of data entry by the 
sites and real -time review of adverse events and safety data. The internal component will also include 
tracking of regulatory documents in an ongoing fashion. If the int ernal processes indicate a problem 
at a site, the need for additional training or oversight will be assessed. A plan will be developed to 
address the needs/issues identified, including addressing the needs via remote methods 
(teleconferences or video confe rences ) in order to minimize the associated costs. If problems persist, 
the CNMC -CC will be updated.  
 
The external component will involve the Project Manager visiting each site at least annually if the site 
has had an episode within that year. The first v isit will be for site initiation. The next visit will occur 
approximately 12 months later. At each visit s /he will monitor the site’s compliance with operational 
protocols, evaluate the site’s data tracking and maintenance procedures, and review all safety  and 
efficacy data points as well as to review all other data in the database against source patient records, 
in compliance with GCP. This visit provides an opportunity to resolve any outstanding queries and 
deal with potential challenges or problems relat ed to protocol adherence, and participant recruitment 
and retention. After each site visit, a monitoring report will be prepared and copies sent to the Study 
File, the CNMC -CC, and the Executive Committee. A follow -up will be initiated to ensure that any 
concerns raised at a monitoring visit are resolved.  
 
Additional reporting and site monitoring will be conducted remotely on a regular basis, including the 
following:    
 Site reports that include simple tabulations of the number of admissions, screened patients, 
eligible patients, ineligible patients, and refusals, by month and cumulatively, as well as the 
observed and expected number of weeks of follow -up on study  
 Subject retention and attrition reports  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 53 of 58 
  Adverse event reports  
 Pharmacy and study drug acco unting activity reports  
 Summaries of the paper -based data captured (e.g., number of forms completed, number of 
forms expected, and the number  of missing pages or fields)  
 Summaries of the electronic data captured (e.g., amount of data captured, amount of da ta 
expected, and the number  of missing fields)  
 DSMB reports  
 
The Coordinating Center will also:  
 Confirm current contact information for all site personnel and study teams  
 Confirm that site delegation logs are up -to-date 
 Review IRB approvals and continuing reviews  
 Obtain documentation of study drug shipment and receipt and sample shipment and receipt  
 Assign database IDs  
 Oversee training for data entry, data management, and pharmacy randomization  
 
10.7 Data Security  
There are several layers of security that protec t the (data) stored in REDCap. The first layer consists 
of network security, through firewalls, and is designed to limit access to the wide -area network (WAN) 
to specific computers and authorized users and to deny access to all others. The firewall blocks 
malware and  prevents flooding. The second layer consists of database authentication. This limits 
access to the database to those individuals passing layer one who has an assigned database 
account and can enter the correct, suitably complex, the user-define d password for that account. The 
third layer consists of controlling a user’s capabilities, what a user can see and do, based on the 
user’s role in each investigation. Each user needing access to the data for a study must be included 
on the list of key sta ff for that specific study in the protocol and must be assigned a study role. If a 
user is not in the key staff list of the study, s/he will not be granted access to that study’s data even if 
s/he has a valid password associated with another study. Key sta ff will only be allowed to perform 
those tasks that are dictated by the person’s defined role in the study. For instance, a person who 
enters data will only be able to add records to specific data files; s/he cannot peruse or make 
changes to existing recor ds in the database. Only those persons who have clinical responsibilities for 
the patient would be able to see the patient  identifying information.   
 
There are also two other components to security and they are monitoring and system administration. 
The ne twork is closely monitored and all activity is logged. Both the real-time monitor and the logs are 
reviewed by eye and by the computer  to identify suspicious activity so that it can be dealt with 
appropriately. Furthermore, all access to research data is a udited and all activities are logged so that 
if a problem occurs it will be possible to identify who was responsible and how it happened. The 
system and database software is kept up -to-date with the latest security protections released for the 
operating sy stem and for the database. These measures help us to keep ahead of the threats to 
security or to close loopholes before they can be more widely exploited. Finally, there is excellent 
physical security; access to the systems is keypad  controlled, there is a  backup generator to provide 
power to keep systems operating in the event of power failure, all computer rooms housing database 
and web servers are environmentally controlled  and protected against flood and fire.  
 
10.8 Data Acquisition and Entry  
 Data collection for this study will be accomplished with online electronic case report forms.   
 On-line forms will be developed that contain the requisite data fields.   
 For each subject enrolled all study -related episodes of the enrollment, diagnostic, 
application, observation, termination and follow -up phases will be recorded in the CRF.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 54 of 58 
  
This CRF must be completed and signed by the investigator for every subject on whose behalf written 
informed consent was given. This also applies to subjects who fail t o complete the study. If a subject 
is being withdrawn from the study by his/her parent(s)/legal guardian(s), the reason must be stated in 
the CRF, if the parent(s)/legal guardian(s) are willing to provide such reason. If a subject is withdrawn 
from the stu dy because of a limiting AE, reasonable efforts should be made to clearly document the 
outcome.  
 All subjects will be identified by their PID.  
 Each investigator will be responsible for ensuring that the identification of his/her subjects is 
possible at an y time.  
 The investigator will be provided with CRF Completion Guidelines from the Coordinating 
Center.  
 These guidelines will provide instructions on how to complete, correct, and archive final 
copies of the CRFs.  
 Prior to the beginning of the study, the investigator must establish a site delegation log, a list 
of the individuals with the trial-related  duties and of the persons authorized to make entries 
and data changes in the CRFs. These persons will be listed, including details on their 
function in the study, their full names, initials, and signatures, and the date of their 
assignment to (and, if applicable, their demission  from) their respective duties on this study.  
 
10.9 Data Editing  
A number of data checks and procedures may be applied during data collect ion that either prevent 
errors or detect them with the requirement for later review and adjudication. No matter what the data 
source all data must pass through all predefined data checks and all potential errors must be 
reviewed and corrected or accepted w ith a comment  using the Data Quality tool in REDCap. Any 
discrepancies are reported in a data exception feedback report for correction and are monit ored to 
ensure that they are accepted or corrected. Predefined procedures and data checks include:  
 Limiting the availability of electronic data entry forms to a defined list of enrollees indexed by 
assigned PID;  
 Implementing validation and consistency checks before data are sent to the database to 
allow correction but logging of all uncorrected exceptions for re quired later review;  
 Checking for and recording on each form the rate of missing data that can be used to set 
criteria for subsequent forms processing, e.g. to reject forms with high missing data rates 
from entering the database;  
 Flagging out of range va lues; and  
 Creating a context sensitive comment window that allows subsequently retrievable text to be 
linked to any form or data item, e.g., to explain an unusual data response.   
 
Web-based, forms allow data to be viewed and edited. Quality assurance chec ks are applied during 
data entry and editing.  In addition to maintaining a time -stamped audit trail of all logins and 
transactions, the system has the capability to be proactive, for example in requiring all unflagged data 
corrections be accompanied by a justification as well as to be adjudicated, reviewed, accepted or 
rejected, by a designee, e.g. a data manager at the Coordinating Center. Together these options and 
procedures promote a high degree of completeness, and accuracy of study data.  
 
10.10  Data Lock and Freeze  
Study data may be preserved by applying electronic security procedures such as ‘locking’ and 
‘freezing’. Locking data (via either partial or final lock) implies a ‘soft lock’ by which approved users 
can make updates to the database. Freezing dat a disallows users to update the data and it only 
allows browsing access. The terms partial lock, final lock, and database freeze are explained below.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 55 of 58 
  
Partial Lock:  
 May be used to lock subsets of data (by site, by the participant , by demographic strata).  
 Is flexible and may be used to:  
o Lock an entire set of participant records at a site;  
o Lock a single participant record; or  
o Lock a single form.  
 Only allows a designated user with update privileges to make updates to the locked 
data.  
 May be applied if data are  not readily available to the sites during study completion (e.g., 
biomarker results produced at the end of the study).  
 
Final Lock : 
 Locks all data entered for a study.  
 Only allows a designated user with update privileges to make updates to the locked 
data. 
 May require entered data to exist in the locked state until the final manuscript is 
submitted to the Coordinating Center.  
 
Database Freeze:  
 Once the CNMC -CC has confirmed the data are satisfactory, the database will be 
frozen.  
 
10.11  Data Entry Training  
Data entry training will be conducted online  using the REDCap database. Study coordinators 
will be trained and certified in the on-line use of the REDCap database. Training sessions will be 
scheduled and organized by the Coordinating Center.  
 
10.12  Data Quality Ass urance  
Data quality is assessed at the data entry point using intelligent review and controls during on -line 
data entry or edits via study forms. Quality assurance (QA)  reports assess data quality post -data 
entry. As we note, data quality begins with the d esign of the data collection forms and procedures and 
incorporates reasonable checks to minimize transcription and omission errors.   Equally important 
quality assurance measures are the internal checks for reasonableness and consistency that will be 
imple mented via simple  tabulations and cross -tabulations  that should reveal any remaining data 
quality issues.  
 
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 56 of 58 
 11 PUBLICATIONS AND OTHER RIGHTS  
 
Since this project is conducted in UCDC sites, we will subscribe to the data and research resources 
sharing plan that have  been developed and approved by the Rare Disease Clinical Research Network.  
According to this plan, datasets  will be made available to the scientific community after publication(s) of 
planned analyses (as set forth in the protocol) of the clinical trial results or no later than 3 years after 
the final visit of the last participant to a clinical trial site, which ever comes first. Data obtained in this trial 
will be presented at national and international meetings and will be published in the medical literature 
with no delays. The investigators are not under any agreement with the provider of the drug to limit or 
delay the publication of data from this trial. Results from this study will also be posted on 
www.clinicaltrials.gov.  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 57 of 58 
 12 REFERENCES  
 
1 Shafai, T.  et al.  Propionic acidemia with severe hyperammonemia and defective glycine 
metabolism. J Ped iatr 92, 84-86 (1978).  
2 Wolf, B., Hsia, Y. E., Tanaka, K. & Rosenberg, L. E. Correlation between serum propionate and 
blood ammonia concentrations in propionic acidemia. J Pediatr  93, 471 -473 (1978).  
3 Whelan, D. T.  et al.  Methylmalonic acidemia: 6 years'  clinical experience with two variants 
unresponsive to vitamin B12 therapy. Can Med Assoc J  120, 1230 -1235 (1979).  
4 Cathelineau, L.  et al.  Occurrence of hyperammonemia in the course of 17 cases of 
methylmalonic acidemia. J Pediatr  99, 279 -280 (1981).  
5 Coude, F. X., Sweetman, L. & Nyhan, W. L. Inhibition by propionyl -coenzyme A of N -
acetylglutamate synthetase in rat liver mitochondria. A possible explanation for 
hyperammonemia in propionic and methylmalonic acidemia. J Clin Invest  64, 1544 -1551, 
doi:10.117 2/JCI109614 (1979).  
6 Batshaw, M. L.  et al.  Treatment of inborn errors of urea synthesis: activation of alternative 
pathways of waste nitrogen synthesis and excretion. N Engl J Med  306, 1387 -1392, 
doi:10.1056/NEJM198206103062303 (1982).  
7 McBride, K. L.  et al. Developmental outcomes with early orthotopic liver transplantation for 
infants with neonatal -onset urea cycle defects and a female patient with late -onset ornithine 
transcarbamylase deficiency. Pediatrics  114, e523 -526, doi:114/4/e523 [pii]  
10.1542/peds.2004 -0198 (2004).  
8 Ah Mew, N.  et al.  Effects of a single dose of N -carbamylglutamate on the rate of ureagenesis. 
Mol Genet Metab  98, 325 -330, doi:S1096 -7192(09)00203 -0 [pii]  
10.1016/j.ymgme.2009.07.010 (2009).  
9 Ah Mew, N.  et al.  N-carbamylgl utamate augments ureagenesis and reduces ammonia and 
glutamine in propionic acidemia. Pediatrics  126, e208 -214, doi:peds.2010 -0008 [pii]  
10.1542/peds.2010 -0008 (2010).  
10 Tuchman, M.  et al.  N-carbamylglutamate markedly enhances ureagenesis in N -acetylgluta mate 
deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. 
Pediatr Res  64, 213 -217, doi:10.1203/PDR.0b013e318179454b (2008).  
11 Filippi, L.  et al.  N-carbamylglutamate in emergency management of hyperammonemia in 
neon atal acute onset propionic and methylmalonic aciduria. Neonatology  97, 286 -290, 
doi:000255168 [pii]  
10.1159/000255168 (2010).  
12 Gebhardt, B.  et al.  N-carbamylglutamate protects patients with decompensated propionic 
aciduria from hyperammonaemia. J Inherit  Metab Dis  28, 241 -244, doi:10.1007/s10545 -005-
5260 -7 (2005).  
13 Gebhardt, B., Vlaho, S., Fischer, D., Sewell, A. & Bohles, H. N -carbamylglutamate enhances 
ammonia detoxification in a patient with decompensated methylmalonic aciduria. Mol Genet 
Metab  79, 303-304, doi:S1096719203000957 [pii] (2003).  
14 Jones, S., Reed, C. A., Vijay, S., Walter, J. H. & Morris, A. A. N -carbamylglutamate for neonatal 
hyperammonaemia in propionic acidaemia. J Inherit Metab Dis  31 Suppl 2 , S219 -222, 
doi:10.1007/s10545 -008-0777 -1 (2008).  
15 Schwahn, B. C., Pieterse, L., Bisset, W. M., Galloway, P. G. & Robinson, P. H. Biochemical 
efficacy of N -carbamylglutamate in neonatal severe hyperammonaemia due to propionic 
acidaemia. Eur J Pediatr  169, 133 -134, doi:10.1007/s00431 -009-1036 -7 (2010).  
16 Guffon, N.  et al.  A new neonatal case of N -acetylglutamate synthase deficiency treated by 
carbamylglutamate. J Inherit Metab Dis  18, 61-65 (1995).  
17 Hinnie, J., Colombo, J. P., Wermuth, B. &  Dryburgh, F. J. N -Acetylglutamate synthetase 
deficiency responding to carbamylglutamate. J Inherit Metab Dis  20, 839 -840 (1997).  
Short -Term Outcome of NCG in Hyperammonemia  
Version 7.1 – 05/01/2020  
Page 58 of 58 
 18 Morris, A. A.  et al.  N-acetylglutamate synthetase deficiency: favourable experience with 
carbamylglutamate. J Inherit Metab  Dis 21, 867 -868 (1998).  
19 Plecko, B., Erwa, W. & Wermuth, B. Partial N -acetylglutamate synthetase deficiency in a 13 -
year-old girl: diagnosis and response to treatment with N -carbamylglutamate. Eur J Pediatr  157, 
996-998 (1998).  
20 Kasapkara, C. S.  et al. N-carbamylglutamate treatment for acute neonatal hyperammonemia in 
isovaleric acidemia. Eur J Pediatr  170, 799 -801, doi:10.1007/s00431 -010-1362 -9 (2011).  
21 Caldovic, L.  et al.  Restoration of ureagenesis in N -acetylglutamate synthase deficiency by N -
carbamylglutamate. J Pediatr  145, 552 -554, doi:S0022 -3476(04)00556 -6 [pii]  
10.1016/j.jpeds.2004.06.047 (2004).  
22 Pollack, M. M.  et al.  Functional Status Scale: new pediatric outcome measure. Pediatrics  124, 
e18-28, doi:124/1/e18 [pii]  
10.1542/peds.2008 -1987 ( 2009).  
23 Woods, R. P., Grafton, S. T., Holmes, C. J., Cherry, S. R. & Mazziotta, J. C. Automated image 
registration: I. General methods and intrasubject, intramodality validation. Journal of Computer 
Assisted Tomography  22, 139 -152. (1998).  
24 Woods, R. P ., Grafton, S. T., Watson, J. D., Sicotte, N. L. & Mazziotta, J. C. Automated image 
registration: II. Intersubject validation of linear and nonlinear models. Journal of Computer 
Assisted Tomography  22, 153 -165. (1998).  
 
 
  
 
 
 